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iv. Abstract 
Human immunodeficiency virus (HIV) associated thrombotic microangiopathy (TMA) is thought to be a 
common form of the disorder in South Africa with a severe clinical presentation and poor prognosis; it 
remains however poorly characterized. This study was undertaken to evaluate the presentation and 
prognosis of HIV-associated TMA through retrospective analysis of a cohort of HIV positive and negative 
subjects diagnosed with and treated for TMA at a single center (Helen Joseph Hospital) from 1/1/2001 
to 31/12/2009. 
HIV-associated TMA was the dominant form of the disorder in this series and was associated with 
advanced HIV infection and a more severe presentation than TMA in HIV negative subjects. Although 
mortality was non-significantly more frequent, response to plasmapheresis was more rapid and 
recurrence less common in HIV positive subjects.   
This study adds to available literature on a rarely studied disorder. Despite its aggressive nature, 
timeous diagnosis and intervention facilitate satisfactory outcomes in HIV-associated TMA.  
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1. Background: The Thrombotic Microangiopathies 
1.1 Introduction 
The thrombotic microangiopathies (TMA) are a heterogeneous group of disorders with a shared 
pathophysiology and clinical presentation (1). Although evidence suggests that HIV infection plays a 
significant role in the aetiology of TMA in South Africa (2), little is known regarding the presentation and 
prognosis of HIV-associated TMA. The present study of a cohort of patients diagnosed with TMA at a 
single institution (the Helen Joseph Hospital) was undertaken in an effort to characterize the 
presentation, response to treatment, and prognosis of HIV-associated TMA.  
1.2 Definitions 
The histopathological term “thrombotic microangiopathy” (TMA) was first used by Symmers in 1952 to 
describe a vascular lesion predominantly affecting capillaries and arterioles characterized by vessel wall 
thickening with swelling and detachment of endothelial cells and intraluminal platelet thrombus 
formation (3). This pathological lesion gives rise to a syndrome first described by Eli Moschowitz in 1925 
in which microangiopathic haemolysis and consumptive thrombocytopaenia are the dominant clinical 
findings (4). Because intraluminal conditions of high sheer force promote microvascular thrombus 
formation, this syndrome is associated with significant renal and / or central nervous system dysfunction 
(5). Following historically important case series descriptions by Singer and Gasser it has been general 
practice to distinguish this clinical syndrome into Thrombotic Thrombocytopaenic Purpura (TTP) or the 
Haemolytic Uraemic Syndrome (HUS) based on the severity of central nervous system or renal 
dysfunction respectively (6 - 9). For reasons set out below TTP and HUS are not viewed as separate 
clinical entities in this study, and the term “thrombotic microangiopathy” is used to refer to the clinical 
disease entity. 
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1.2.1 TMA – a unified model of TTP-HUS 
It has been historically accepted that TTP and HUS are clinically distinct disorders, with TTP comprising a 
syndrome of microangiopathic haemolysis, consumptive thrombocytopaenia, neurological deficit of 
varying severity, pyrexia and minimal or no renal dysfunction; and HUS featuring microangiopathic 
haemolysis, consumptive thrombocytopaenia, renal dysfunction and no pyrexia or neurological deficit (6 
- 8). It was postulated that the discrepancies in organ involvement between these two disorders arose as 
a result of preferential sites of TMA lesion development (viz., the central nervous system in TTP and the 
kidneys in HUS) (10, 11).  
Some evidence suggests that TTP and HUS have unique aetiologies and pathophysiologies. In 1982 
Moake demonstrated the presence of prothrombotic ultralarge monomers of von Willebrand factor 
(ULvWF) in the sera of patients with TTP (12); later efforts by Furlan, Tsai, Levy and Gerritsen showed 
that this anomaly arose as a result of congenital or acquired defects in ADAMTS13 activity (13 - 19). TTP 
occurring in systemic lupus erythematosus (SLE), the antiphospholipid syndrome (APLS), HIV infection 
and with ticlopidine use has been shown to be associated with the presence of inhibitory ADAMTS13 
antibodies (20 - 23). 
These findings have suggested that ADAMTS13 deficiency (either acquired or congenital) is central to 
the development of TTP. Diminished ADAMTS13 activity allows the accumulation of ULvWF which under 
the high sheer force conditions produced by blood flow through the microvasculature leads to the 
formation of ULvWF strings anchored to the endothelium by P-selectin (ADAMTS13 is responsible for 
the cleavage of ULvWF into smaller, less thrombotic dimers)(24, 25). The formation of these strings 
provides multiple sites for platelet binding and activation via the glycoprotein IbIX – factor V complex 
and / or platelet integrin IIb , leading to extensive platelet thrombus formation within the 
microvasculature, consistent with the TMA lesion (25). It has been suggested that the association of 
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ADAMTS13 deficiency with TTP is sufficiently robust to allow ADAMTS13 activity levels to be used as a 
diagnostic tool for the disorder (20, 26). 
 In contrast, HUS is usually (90% of cases) the result of infection with shigatoxin producing Escherichia 
coli, Shigella dysenteriae type 1, or Citrobacter freundii (9, 27). Shigatoxin has been shown to induce 
endothelial cell dysfunction through disruption of protein synthesis and upregulation of prothrombotic 
pro-inflammatory cytokines (28, 29). Acquired or congenital defects in the complement regulatory 
pathway involving complement factor H (CFH), complement factor I (CFI), membrane cofactor P (MCP), 
complement factor B (CFB), complement factor 3 (C3) or thrombomodulin have been implicated in the 
rare atypical (non-diarrhoeal) forms of HUS (27, 30, 31). 
Although such findings appear to suggest that TTP and HUS can be viewed as separate disease entities, 
significant evidence has emerged to suggest that they are best interpreted as opposing extremes of a 
clinical syndrome caused by a single disorder of multiple aetiologies. For example, metanalysis of the 
available case series reports of TTP indicate that significant renal dysfunction may occur in up to 80% of 
patients (11). Indeed, acute renal injury severe enough to require dialysis has been reported in some 
patients with severely deficient ADAMTS13 activity (a finding supposedly diagnostic of TTP) (32). 
Neurological deficit has been reported to occur in both atypical and diarrhoea-associated HUS (33), and 
autopsy series have found evidence of cerebral microcirculation TMA lesions in up to 50% of patients 
diagnosed with this disorder (11). Magnetic resonance imaging of the brain has also shown CNS 
involvement in patients diagnosed with HUS (34, 35). Analysis of a large patient cohort found that the 
diagnostic pentad of TTP (microangiopathic haemolysis, consumptive thrombocytopaenia, pyrexia, 
minimal renal dysfunction, and cerebral dysfunction) did not occur in any patient in the series (n = 142) 
(32). Other series have also demonstrated that ADAMTS13 deficiency is not specific for TTP and may also 
occur in congenital HUS (36).  
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Thus, TTP and HUS show overlapping clinical features and share many aetiological factors. TTP and HUS 
therefore represent the variable clinical presentation of a number of different aetiologies which are 
capable of inducing TMA. Endothelial dysfunction is known to be central to the development of TMA in 
several disorders including atypical HUS (complement-mediated injury to the endothelium) (27), 
diarrhoea-associated HUS (shigatoxin-induced endothelial apoptosis) (29, 37), mitomycin and 
calcineurin inhibitor induced TTP (1, 9), HIV-associated TTP (38), and transplantation-associated TTP (39, 
40). TMA can therefore be viewed as the pathological evidence of underlying endothelial dysfunction 
caused by these heterogeneous disorders. Supporting this approach is the observation that serum from 
patients with both idiopathic TTP and atypical HUS has been shown to directly induce endothelial cell 
apoptosis (41, 42) through as yet poorly defined pathways involving Fas and caspase-8 (42, 43). Animal 
models provide further corroboration of the central role of endothelial dysfunction in the development 
of the TMA lesion underlying the clinical syndromes of TTP and HUS: Vascular Endothelial Growth Factor 
(VEGF) knockout mice have been shown to spontaneously develop TMA lesions (44), the administration 
of antiendothelial cell antibodies has resulted in TMA lesions developing in a rat model (45), and an 
ADAMTS13 deficient murine model of TTP failed to develop TMA lesions until exposed to intravenous 
collagen and epinephrine, thus suggesting that ADAMTS13 deficiency itself is not sufficient to induce 
TMA but may require a “second hit” perhaps in the form of a prothrombotic state resulting from 
endothelial dysfunction (46). Significantly, endothelial dysfunction is known to result in the upregulation 
of ULvWF production as well as P-selectin (24, 47); under these circumstances, ADAMTS13 would rapidly 
become depleted. Thus, a primary defect in endothelial function may be sufficient to account for the 
ADAMTS13 deficiency model of TTP proposed to uniquely account for the development of this disorder. 
For the above reasons it is increasingly apparent that TTP and HUS are not separate entities but rather 
variable clinical presentations of a single disorder characterised by endothelial dysfunction (1, 11). In the 
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analysis presented here the terms TTP and HUS are therefore not used, and for clarity the disorder is 
referred to as “TMA”. 
1.3 Epidemiology of TMA 
TMA is estimated to have an annual incidence of 4/1 000 000 (48). Some reports have suggested that 
the incidence of TMA is rising although this may reflect improved disease surveillance (49, 50). A female 
preponderance has been reported in most case series (1, 48, 51). The disorder commonly affects 
individuals between the ages of 20 and 60 years (48). Persons of Black African descent are more likely to 
be affected with TMA than other race groups, and it has been suggested that Black African descent is a 
risk factor for acquired autoimmune forms of the disorder (1, 22, 51).  
1.3.1 Epidemiology of HIV-associated TMA 
The reported contribution of HIV infection to TMA incidence is highly variable (52) and likely reflects 
geographic differences in HIV prevalence. Analysis of the large TMA cohort of the Oklahoma TTP-HUS 
Registry found that HIV-associated TMA accounted for 1.8% of all cases of the disorder (52). This low 
incidence of HIV-associated TMA is consistent with the low observed incidence of TMA (0.3%) amongst 
the 6022 HIV positive patients enrolled in the Collaborations in HIV Outcomes / Research US study (53). 
In contrast, a single case series from South Africa appears to indicate that HIV-associated TMA is the 
most common form of the disorder in our setting (2).  
TMA in HIV positive patients may occur as a complication of antiretroviral drugs (chiefly abacavir) (55), 
as a component of the Immune Reconstitution Inflammatory Syndrome (IRIS) (56), as a consequence of 
opportunistic infections such as CMV (57), or as a consequence of the HI virus itself. The central role of 
the HI virus in the pathogenesis of HIV-associated TMA is highlighted by case reports of this disorder 
responding to initiation of combination antiretroviral therapy (cART) and, in other case reports, the 
recurrence of TMA in patients discontinuing cART (38). HIV may induce TMA through the development 
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of ADAMTS13 antibodies (22, 38); however, ADAMTS13 antibodies are not universally present in 
patients with HIV-associated TMA (54, 58). Instead, it is likely that HIV-associated TMA occurs as a result 
of endothelial dysfunction. The HI virus is able to infect endothelial cells through mutations to the gp120 
envelope protein (59, 60), following which the endothelial cell may undergo caspase-8 mediated 
apoptosis (43).  
The direct role of the HI virus in causing HIV-associated TMA probably accounts for the observed 
tendency for HIV-associated TMA to occur in patients with low CD4 count and other features of 
advanced infection stage (51, 53, 54, 61). The disorder in local literature demonstrates a strong female 
preponderance (female to male ratio 20:1) (51); whereas in international literature case studies have 
shown a higher rate of male patients (up to 80% of cases) (62). This discrepancy likely reflects 
geographical variation in gender distribution of HIV infection. In North America and Europe HIV infection 
is mainly acquired through male to male sexual contact; as a result, 73% of patients living with HIV 
infection in the United States are male (63). In contrast, in South Africa HIV infection is acquired through 
heterosexual contact; as a result, women bear the brunt of HIV infection in the local setting with up to 
55% of patients living with the infection being female (64). 
1.4 TMA in the context of HIV infection 
1.4.1 The presentation of HIV-associated TMA 
It is generally believed that HIV-associated TMA is more severe in clinical presentation than TMA seen in 
HIV negative patients, although data in this regard is scarce. Local experience suggests that several 
parameters of TMA including markers of microangiopathic haemolysis (haemoglobin concentration and 
lactate dehydrogenase activity), consumptive thrombocytopaenia (platelet count), and renal 
dysfunction (serum creatinine) may be more severely abnormal in HIV-associated TMA (51). 
Furthermore, neurological deficit may be more frequent in HIV-associated TMA (51). 
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 It remains unclear whether the severity of clinical presentation in HIV positive patients is solely a 
function of the TMA disease process, or whether other HIV infection-related pathophysiologies may be 
contributing. For example, anaemia is widely prevalent in advanced HIV infection (63 – 95% of patients) 
and may be due to multiple other HIV-related disease processes besides microangiopathic haemolysis, 
including nutritional anaemia, anaemia of chronic disease, and red cell aplasia due to antiretroviral 
drugs (65). Similarly, thrombocytopaenia in HIV positive patients may be exacerbated by other disease 
processes (for example, immune thrombocytopaenia, malnutrition, bone marrow infiltration) occurring 
concomitantly with the consumptive thrombocytopaenia of TMA (66). Renal dysfunction may also be a 
common associate of HIV infection with prevalence rates of up to 27% reported in some series (67); 
thus, the apparent severity of renal dysfunction in HIV-associated TMA may in part be due to underlying 
pre-existing renal disease. 
Some evidence that the TMA disease process itself may be the most significant determinant of the 
severity of clinical presentation in HIV-associated TMA is to be found in reports that higher levels of D-
dimer are observed in this form of the disease (2, 54).  It has been suggested that this finding is 
indicative of a unique pathophysiology involved in HIV-associated TMA (2). D-dimers are the cleavage 
products of fibrin and reflect activation of the fibrinolytic system in response to thrombus formation 
(68); thus, a higher D-dimer level may be indicative of more extensive microthrombus formation 
occurring in HIV-associated TMA. It is however also known that HIV infection itself appears to increase 
D-dimer levels which have been shown to correlate with HIV viral load (69); this is consistent with the 
prothrombotic state induced by HIV infection (70). Thus, the severity of clinical presentation of HIV-
associated TMA may be due to extensive microvascular thrombus formation precipitated by endothelial 
dysfunction caused by infection of these cells by the HI virus, aided by the prothrombotic background 
which is a consequence of HIV infection. 
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Although microangiopathic haemolysis and consumptive thrombocytopaenia are characteristic systemic 
features of TMA, a subset of patients may present with a renal limited form of the disorder in which 
these abnormalities are not readily detected (71). Renal limited HIV-associated TMA has been described 
(58, 72), and although the prevalence of this form of the disorder is uncertain (since diagnosis rests on 
renal biopsy, itself requiring a high index of suspicion on the part of the treating physician) (73), 
available literature suggests that 7 – 15% of HIV-associated TMA may be renal-limited (58, 72). 
1.4.2 Response to therapy of HIV-associated TMA 
Plasma exchange using fresh frozen plasma (FFP) or cryosupernatant plasma has become the mainstay 
of therapy for TMA (74). Originally described by Bukowski et al in 1977 (75), the use of plasmapheresis 
has improved survival rates in TMA from 10% to between 75% and 92%% (74). Patients at both the HUS 
and TTP ends of the clinical spectrum of TMA presentation have shown response to plasma exchange 
(76, 77). Interestingly, plasmapheresis was also shown to be of benefit in adult patients diagnosed with 
diarrhoeal HUS during a 1996 outbreak in Scotland (78). Based on these and other studies the British 
Committee for Standards in Haematology now recommends plasmapheresis as standard first-line 
therapy for all cases of TMA (79, 80).  
The beneficial effect of plasma exchange in TMA occurs as a result of the removal of excessively 
thrombogenic and anti-fibrinolytic molecules and the replacement of deficient anticoagulants and 
profibrinolytic molecules in order to regain the normal milieu of haemostasis (81). Thus, plasmapheresis 
allows for the removal of ULvWF, ADAMTS13 autoantibodies and inhibitors, interleukin 6 (known to 
stimulate ULvWF release from the endothelium), and thrombin; and to allow for the replenishment of 
ADAMTS13 (81 - 83). Since cryosupernatant plasma is ULvWF depleted, it has been thought that this 
may be the preferable replacement plasma for TMA patients receiving plasmapheresis (84); however, 
this has not been shown in prospective studies (85). 
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Remission of HIV-associated TMA and prevention of relapse is dependent on improving the immune 
status of the patient; for this reason, the British Committee for Standards in Haematology recommends 
urgent initiation of cART in this disorder in addition to plasma exchange (80).  
Despite such recommendations, controversy exists as to the responsiveness of HIV-associated TMA to 
therapeutic intervention, mainly as a result of the paucity of data available in this regard. Tamkus et al, 
Abraham et al and Tostivint et al have reported  mortality rates higher than those seen in HIV negative 
patients despite the use of standardized therapy (86 - 88), suggesting poorer responsiveness. However, 
Miller et al have reported a similar therapeutic response in terms of survival rates in HIV-associated TMA 
compared to that seen in HIV negative patients (38), and Novitzky et al have shown lower mortality 
rates in HIV positive patients compared to HIV negative patients (51). This latter study also provides the 
only interrogation of the rate of response as a function of time of HIV-associated TMA compared to TMA 
in HIV negative patients, demonstrating a more rapid induction of remission in the former group (51). 
1.4.3 Prognosis of HIV-associated TMA 
The prognosis of HIV-associated TMA must be interpreted in the context of 3 main outcomes of therapy, 
viz. mortality rates, residual target organ deficit (neurological and renal), and recurrence rates.  
1.4.3.1 Mortality 
As previously noted, controversy exists regarding the mortality rates observed in HIV-associated TMA, 
with mortality rates variously reported as higher, equal to, and lower than those seen in HIV negative 
patients (38, 51, 86 - 88). Data from other series have additionally suggested that the occurrence of TMA 
in an HIV positive patient predicts mortality even if the TMA episode is successfully treated, with patient 
death ensuing within 1 – 2 years of diagnosis of TMA (61, 89), an observation which may reflect the 
association of the disorder with advanced HIV infection (51, 53, 54, 61, 89). Mortality in patients with 
HIV-associated TMA has been suggested to be associated with neurological signs (86) and high LDH 
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activity at presentation (90). In view of the paucity of data concerning mortality in HIV-associated TMA, 
consideration may be given to that available from analysis of TMA occurring in HIV negative patients in 
order to extrapolate risk factors for death from TMA to HIV positive patients. In so doing, however, it 
should be stated that the accuracy of such data may itself be limited by the retrospective nature of 
many of the case series from which this data is derived, which results in bias due to the inclusion of 
cases of TMA from a variety of causes (which may have differing prognoses) as well as the inclusion of 
multiple confounding factors (90). Neurological deficit, older age (>40 years), lower haemoglobin (< 
6.5g/dl), lower platelet count (< 15x109/l), pyrexia (> 38.5oC), and renal dysfunction (creatinine > 
175 mol/l) have been described in various series to be associated with mortality (91 - 93). 
1.4.3.2 Residual target organ dysfunction 
Neurological deficit in TMA is thought to arise through two main mechanisms; microinfarction as a result 
of microthrombus formation, and endothelial dysfunction leading to fluid transudation and petechial 
haemorrhage through the resultant disrupted blood-brain barrier (94). Case series using imaging with 
computerised tomography (CT) or magnetic resonance imaging (MRI) indicate the latter to be the more 
common pathophysiology (94). This results in a reversible posterior leukencephalopathy syndrome, 
which most commonly presents with confusion and/or lethargy but may include hemiparesis (94). The 
response of serious neurological symptoms such as hemiparesis and altered levels of consciousness to 
plasma exchange is usually rapid and permanent clinically obvious neurological deficits are rare (74, 94), 
but subtle abnormalities of cognitive function including concentration and memory may be an 
underappreciated and frequent sequelae (74). The latter consideration, and the observation that 
neurological dysfunction in TMA may be multifactorial in origin (including for example, electrolyte 
disturbances caused by renal dysfunction) (35), the use of data from retrospective studies (in which the 
severity of neurological dysfunction is unclear and may be over-emphasised) (90), and the prevalence of 
neurological abnormality in HIV positive patients (40-60% of patients with advanced HIV infection may 
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have some degree of neurological deficit) (95) combine to make analysis of the response of neurological 
dysfunction in HIV-associated TMA difficult. 
The response of renal dysfunction caused TMA in general to standard therapy remains controversial. 
Tostivint has found that plasma-based therapies result in 73.3% of patients with TMA recovering normal 
renal function (89). Hollenbeck has reported that the use of plasma exchange led to an 81.8% reduction 
in the relative risk of developing end-stage renal disease (96). In contrast, Schieppati et al have reported 
that 70% of patients with TMA have some degree of on-going renal dysfunction despite therapy, with 
26% developing end-stage renal disease requiring dialysis (97). In this series, a poor renal outcome was 
associated with a higher creatinine at presentation, lower presenting haemoglobin, and a higher 
presenting platelet count; this suggests that established or background renal dysfunction at 
presentation determines the likelihood and severity of residual renal dysfunction rather than the 
severity of presentation of TMA (97). This is consistent with Tostivint et al’s report indicating that the 
presence of an underlying renal disease and requirement for dialysis during hospitalization are 
independent risk factors for chronic renal insufficiency, whereas a high LDH at presentation (indicative 
of TMA severity) was associated with better renal outcomes (89).  
The response of HIV-associated TMA to standard therapy remains uncertain, mainly because of the 
limited data available in this regard. Gervasoni et al have reported that the use of plasma exchange is 
associated with resolution of TMA lesions in the renal biopsy specimens of patients with HIV-associated 
TMA (98); however, large patient cohort studies confirming this finding are not available. Analysis of the 
response of renal dysfunction in HIV-associated TMA is further complicated by the prevalence of 
background renal dysfunction in patients living with HIV (67) and the probability that renal dysfunction 
in the disorder may be due to other concomitant factors, such as dehydration due to altered levels of 
consciousness or diarrhoea secondary to opportunistic infections.  
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1.4.3.3 Recurrence 
Available literature suggests a wide disparity in the rate of recurrence of TMA dependent on the 
aetiological factors involved. Whilst relapse of diarrhoeal HUS is extremely rare (9), the rate of 
recurrence is higher in patients with congenital defects in complement regulation or ADAMTS13 activity 
(27). TMA secondary to autoimmune disorders may also be associated with a higher rate of recurrence 
(99). In acquired forms of TMA associated with ADAMTS13 deficiency the risk of recurrence may depend 
on the severity of ADAMTS13 deficiency present when in remission (27, 99). Overall, 15 – 30% of 
patients with TMA experience a recurrence of the disorder (27, 100). Whilst Tuncer et al have suggested 
that a lower platelet count at presentation may identify patients at risk of recurrence (91), in general, 
clinical parameters at presentation do not predict recurrence (101, 102).  
Recurrence of HIV-associated TMA is rare in patients commenced on antiretroviral therapy (51); 
significantly, however, recurrence may be precipitated by patients discontinuing cART (38). Isolated case 
series have also suggested that deficiency of ADAMTS13 detected in HIV positive patients in TMA 
remission may also predict risk of recurrence (103). 
Recurrent TMA appears to respond well to plasma exchange (104, 105), and the risk of mortality in 
patients experiencing TMA recurrence appears to be very low (90). It is likely that the better mortality 
outcomes observed in recurrent TMA reflects earlier diagnosis and therapeutic intervention as a result 
of improved symptom recognition on the part of patients or frequent symptom and laboratory 
parameter surveillance on the part of attending medical staff (90). 
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1.5 Summary 
The Thrombotic Microangiopathies represent a group of heterogeneous disorders which act through the 
shared pathophysiological mechanism of endothelial dysfunction to produce a syndrome characterised 
by microangiopathic haemolysis and consumptive thrombocytopaenia with varying degrees of target 
organ injury chiefly affecting the central nervous and renal systems. A single case series suggests that 
HIV may be the dominant cause of TMA in the local setting (2). HIV-associated TMA has been poorly 
studied, and the presentation of the disorder, response to treatment (plasma exchange), and prognosis 
(including mortality rates and likelihood of residual target organ dysfunction) are poorly characterized 
and therefore remain areas of controversy. The study presented here was undertaken with the aim of 
better characterizing HIV-associated TMA. 
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2. Study design: a retrospective analysis of TMA in the era of HIV 
2.1 Study objectives 
This study was undertaken with the aim of better characterizing the presentation, response to a 
standardized therapy using plasma exchange, and the prognosis of HIV-associated TMA. The 
presentation of HIV-associated TMA was analysed in respect of the following: 
1. The epidemiology and demographics of patients presenting with TMA 
2. Clinical and laboratory parameters measured at TMA presentation. 
The response to plasma exchange was analysed in respect of the following: 
1. The number of plasma exchange sessions required to induce remission of TMA 
2. The improvement of clinical and laboratory parameters in response to plasma exchange 
3. Complications of plasma exchange 
The effect of the type of plasma replacement used (FFP or cryosupernatant plasma) on response to 
therapy was also characterized in respect of 1. and 2. above. 
The prognosis of the disorder was analysed in respect of the following: 
1.  Mortality in  subjects diagnosed with TMA 
2. Residual renal dysfunction following treatment with plasma exchange 
3. The recurrence of TMA following plasma exchange 
In order to determine whether the presentation, therapeutic response, and prognosis of HIV-associated 
TMA differ from that seen in other forms of the disorder, results of the above analyses were also 
compared to data derived from HIV negative subjects diagnosed with and treated for TMA during the 
period of the study. 
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2.2 Patients and methods 
2.2.1 Study population 
Data used in this analysis was obtained from those subjects diagnosed with TMA at the Helen Joseph 
Hospital (HJH) between 1/1/2001 and 31/12/2009. HJH is a secondary level hospital which serves the 
western areas of Johannesburg. The patient population resident in these areas is heterogeneous and 
includes patients of African, Asian, Indian, Caucasoid and Coloured (mixed race) ancestry. During the 
time period of this study a total of 40 subjects were diagnosed with TMA, comprising 35 HIV positive 
subjects, 4 HIV negative subjects, and 1 subject who demised before HIV serological testing could be 
undertaken. Seven subjects subsequently suffered a recurrence of TMA following standard therapy, so 
that there were a total of 47 separately treated instances of TMA during the course of this study. 
2.2.2 Data collection 
Subjects potentially suitable for inclusion in this study were identified from a registry of patients known 
with TMA maintained by the Department of Haematology at HJH. Since all patients with suspected TMA 
at the hospital are referred to this department for management this approach identified all known 
cases. Case files for all patients diagnosed with TMA between 1/1/2001 and 31/12/2009 were obtained 
and retrospectively reviewed. The closing date for this series reflects the period of protocol submission 
for this study. In cases where data was incomplete resort was made to the electronic records of the 
National Health Laboratory Service (NHLS) at the hospital. 
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2.2.3 Inclusion criteria 
Patient data was included in this series where: 
1. Retrospective review confirmed the original diagnosis of TMA using criteria accepted by the 
British Committee for Standards in Haematology and by the authors of the large Oklahoma TTP-
HUS Registry (1, 79, 80), specifically: 
a. Evidence of microangiopathic haemolysis (anaemia, red cell fragments on peripheral 
smear, and elevated serum LDH activity), and 
b. Evidence of consumptive thrombocytopaenia 
c. No other cause for the above apparent 
Because data from the Oklahoma TTP-HUS Registry indicates that the full pentad of TTP rarely occurs 
(1), the presence of features other than 1a and 1b above (viz., pyrexia, neurological abnormality, and 
renal dysfunction) were not used as diagnostic criteria. Since histological evidence of TMA (for example, 
from renal biopsy) is not required for the diagnosis of the disorder by either the British Committee for 
Standards in Haematology or the Oklahoma TTP-HUS Registry (1, 79, 80), inclusion in this study did not 
require this criteria to be met. 
2. In view of data suggesting that TTP and HUS are variable clinical manifestations of the same 
underlying disorder (TMA) no attempt at distinction was made in this series between these two 
clinical syndromes. In so doing this analysis follows the convention of the Oklahoma TTP-HUS 
Registry (1). 
Both HIV positive and HIV negative patients were included in this study in order characterize HIV-
associated TMA against TMA seen in HIV negative patients. 
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2.2.4 Exclusion criteria 
Patients were excluded from enrollment in this series where: 
1. Retrospective review indicated an incompleteness of data and / or follow up which might 
otherwise affect statistical analysis 
2. Retrospective review indicated another possible aetiology for the clinical and laboratory data 
recorded, namely: 
a) Disseminated Intravascular Coagulopathy (DIC) 
b) Malignant hypertension 
c) Pre-eclampsia / eclampsia 
d) Scleroderma renal crises. 
2a) DIC was retrospectively diagnosed if patients had evidence of an elevated International Normalized 
Ratio (INR) and other recorded data consistent with known precipitant of DIC.  
2b) Malignant hypertension was retrospectively diagnosed if case files demonstrated the presence of 
elevated blood pressure (systolic BP > 140mmHg or diastolic BP > 90mmHg) on two occasions with 
evidence of renal dysfunction (abnormal blood urea, electrolyte and creatinine tests with confirmed 
proteinuria and / or dysmorphic erythrocytes on urinalysis) and recorded evidence of a grade 3 or 4 
hypertensive retinopathy (haemorrhages and exudates or papilloedema) in addition to microangiopathic 
haemolysis and consumptive thrombocytopaenia (106). 
2c) Pre-eclampsia / eclampsia was diagnosed if the patient had recently been pregnant (< 6 months 
post-delivery), was hypertensive (systolic BP > 140mmHg and / or diastolic BP > 90mmHg), and had 
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proteinuria, with or without evidence of encephalopathy or seizure, in addition to the features of 
malignant hypertension discussed above (107). 
2d) Patients were retrospectively considered to have evidence of scleroderma renal crisis where there 
was evidence of renal dysfunction with active urinary sediment (proteinuria and / or dysmorphic 
erythrocytes on urine microscopy) with seropositivity for scleroderma (anticentromere or 
antitopoisomerase antibodies positive) (108). 
2.2.5 Definitions of clinical disease categories associated with TMA in this series 
Patients included in this series and diagnosed as being HIV positive or admitted with this diagnosis 
already established were retrospectively validated as HIV positive if review of laboratory results satisfied 
established World Health Organization criteria (109), namely: 
1. Positive HIV antibody testing (either rapid or laboratory-based enzyme immunoassay) confirmed 
by a second HIV antibody test (either rapid or laboratory-based enzyme assay) relying on 
different antigens or different operating characteristics; or 
2. Positive virological test for HIV or its components (HIV-RNA or HIV-DNA or ultrasensitive HIV p24 
antigen) confirmed by a second virological test obtained from a separate determination. 
Patients included in this series who were diagnosed with Systemic Lupus Erythematosus (SLE) or who 
were admitted with the diagnosis of TMA on a background of previously diagnosed SLE were 
retrospectively validated as having SLE if case review documented the presence of at least 4 of the 11 
criteria proposed by the American College of Rheumatology within a 6 month period (110). 
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2.2.6 Statistical analysis 
Analysis of data in this series was performed using Statistica™ version 9 (series 231.14) statistical 
software (Statsoft®). Statistical significance was determined by a p < 0.05. 
 Assessment of the normality of distribution of continuous variables was performed using the Shapiro-
Wilk W test and in consideration of the Central Limit Theorem. Because most variables analysed were 
not shown to be normally distributed, the distribution of continuous variables analysed in this series is 
presented with central tendency being represented by the median, and the dispersion measurement 
being given by the range and interquartile range (IQR). 
Testing of data sets was performed using the Mann-Whitney U test for non-parametric independent 
continuous variables. Analysis of association was undertaken using the Spearman rank order method. 
The predictive role of variables analysed for certain outcomes in this series was performed using the 
ordinary least squares method of linear regression. Comparative analysis of categorical variables was 
made using a two-tailed Fisher exact test. 
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3. Results 
3.1  The Epidemiology and Demographics of HIV-associated TMA 
Thirty-nine of the 40 subjects included in this series were tested for HIV infection on presentation with 
TMA (97.5%); one subject demised before testing could be performed. Of those tested, 35 subjects 
(89.74%) were found to be HIV positive and 4 (10.26%) were found to be HIV negative, thus giving a 
ratio of HIV positive to HIV negative subjects of 8.75:1.  
Amongst the HIV positive subjects, 23 were newly diagnosed with the infection (65.71%) and 12 were 
known to be HIV positive before presentation with TMA (34.29%). Three of the subjects who were 
previously known to be HIV positive had already been initiated onto combination antiretroviral therapy 
(cART) before presentation with TMA (25% of subjects known to be HIV positive before presentation 
with TMA,  and 8.57% of all HIV positive subjects in this series). The range of duration of cART in these 
patients was 3 – 7 days (median 6 days).  None of these patients received a drug regimen containing 
abacavir, and it is unlikely that CART was an aetiological factor in their subsequent presentation with 
TMA. The median age amongst HIV positive subjects was 33 years (IQR 28 - 40 years and range 23 – 62 
years). Twenty-six subjects were female (74.3%) and 9 were male (25.71%); the female to male ratio was 
2.89:1. Thirty-four subjects were of Black African descent; 1 subject was of Mixed Race (Coloured) origin 
and there were no Indian or Caucasian subjects in this subgroup; the Black African to non-black ratio 
was thus 34:1. 
Amongst the HIV negative subjects who presented with TMA during the course of this series, 3 fulfilled 
American College of Rheumatology criteria for the diagnosis of Systemic Lupus Erythematosus (SLE) 
(75% of HIV negative subjects and 7.5% of all patients in this series) (110). In one subject no definitive 
underlying aetiology could be determined despite intensive investigation; this subject was labeled as a 
case of idiopathic TMA (25% of all HIV negative subjects in this series and 2.5% of all subjects in this 
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series. The median age of HIV negative subjects was 40.5 years (IQR 28 – 44.5 years, range 17 – 67 
years). All subjects (100%) were female. 2 subjects were of Mixed Race (Coloured) origin (50%), and one 
subject each was of Black African and Indian descent (25% each). The Black African to non-black ratio 
was thus 1:3. 
Thus, a preponderance of female subjects overall was noticed in this series. Two-tailed Fisher Exact 
testing did not reveal a statistically significantly higher frequency of female subjects in the HIV negative 
subject group (p = 0.556). In contrast, the preponderance of subjects of Black African descent with HIV-
associated TMA was shown to be statistically significant (p = 0.002) (table 3.1). 
Table 3.1 1 Epidemiology and demographics of TMA at Helen Joseph Hospital, 2001 - 2009 
 HIV positive subjects HIV negative subjects 
p 
 N (% of total) / median (IQR) N (% of total) / median (IQR) 
HIV infection  N = 35 (89.7%4) N = 4 (10.26%) 
 
Age (years) 33 (23 – 62) 40.5 (28 – 44.5) 
Sex 
Female: N = 26 (74.3%) 
Male:  N = 9 (25.71%) 
Female: N = 4 (100%) 
Male: N = 0 (0%) 
0.556* 
Race 
Black African: N = 34 (97.14%) 
Mixed Race: N = 1 (2.86%) 
Caucasian: N = 0 (0%) 
Indian: N = 0 (0%) 
Black African: N = 1 (25%) 
Mixed Race: N = 2 (50%) 
Caucasian: N = 0 (0%) 
Indian: N = 1 (25%) 
0.002* 
*Fisher Exact test 
Three episodes of TMA in this series occurred following pregnancy. Two of these presentations occurred 
in two subjects who were subsequently diagnosed with SLE. Both of these subjects experienced 
subsequent episodes of TMA exacerbation which were not associated with pregnancy, which suggests 
that in both of these cases SLE was the dominant aetiological factor of TMA. In both subjects there was 
no evidence of secondary antiphospholipid syndrome. One case of peripartum TMA occurred in an HIV 
positive subject. This subject had no other episodes of TMA or further pregnancies during the course of 
this series, and it is difficult to establish which of these two possible aetiologies was dominant. 
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3.2 Presenting features of HIV-associated TMA 
The following presenting features were analysed in this study: pyrexia, neurological abnormality, serum 
haemoglobin concentration, LDH activity, presence of red cell fragments, reticulocyte production index 
(RPI), platelet count, D-dimer concentration, urea concentration, and creatinine concentration (table 
3.2.1). All cases of TMA included in this series had systemic manifestations of microangiopathic 
haemolysis (anaemia, raised LDH activity and red cell fragments detected on peripheral blood smear) 
and consumptive thrombocytopaenia (platelet count below laboratory normal). No cases of renal 
limited disease were identified during the course of this series. 
Table 3.2 1 Presenting features of TMA in HIV positive subjects 
 Valid N 
(%)* 
N 
(%)** 
Median IQR Range 
Oral temperature (oC) 17 (44.7) 7 (41.2) 37.0 36.7 – 37.5 36.0 – 38.0 
LDH activity (IU/l) 38 (100) 38 (100) 1549 1208 - 2289 465 – 4554 
Fragments observed 
+ 
++ 
+++ 
38 (100) 
 
 
 
38 (100) 
6 (15.8)# 
5 (13.2)# 
27 (71)# 
   
Platelet count (x109/mm3) 38 (100) 38 (100) 17 13 - 48 7 – 127 
Haemoglobin (g/dl) 38 (100) 38 (100) 6.35 5.0 – 7.1 2.8 – 9.3 
RPI 29 (76.3) 21 (72.4) 1.9 0.9 – 3.1 0.03 – 9.2 
D-dimer (mg/l) 23 (60.5) 23 (100) 3.53 2.4 – 5.4 0.3 – 20.0 
Urea (mmol/l) 38 (100) 27 (71.1) 10.3 5.7 – 14.6 1.7 – 36.9 
Creatinine ( mol/l) 38 (100) 28 (73.4) 127 97 - 252 50 – 651 
Neurological deficit 
Confusion 
Headache / dizziness 
Generalized seizure 
Focal deficit 
 
25 (65.8) 
15 (60)## 
5 (20)## 
3(12)## 
2 (8)## 
 
CD4 count (x106/mm3) 37 (97.4) 36 (94.7) 115 42 - 250 6 - 744 
* Valid N = subjects for whom data is available, % = % of series as a whole, **N = subjects with abnormal 
values, % = % of subjects with abnormal values of those subjects with available data, #% of all subjects 
with fragments ##% of all subjects with neurological deficit 
 
41.2% of subjects presenting with HIV-associated TMA in whom oral temperature was documented on 
admission were pyrexial, and 65.8% had neurological abnormality. The presence of pyrexia or 
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neurological deficit was not more frequent in HIV positive subjects when compared to HIV negative 
subjects in this series (two-tailed Fisher Exact test p = 0.624 and p = 0.657 respectively). Measured oral 
temperature was not significantly different in HIV positive subjects at presentation (p = 0.505 in two-
tailed Mann Whitney U test) (table 3.2.2).  
Table 3.2 2 Comparison of presenting features by HIV infection status 
 HIV positive subjects HIV negative subjects p 
Pyrexia  7 (41.2)* 5 (62.8)* 0.624# 
Neurological abnormality 25 (65.8)* 7 (87.5)* 0.657# 
Oral temperature (oC) 37.0 (36.7 – 37.5)** 37.5 (37 – 37.8)** 0.505## 
LDH activity (IU/l) 1549 (1208 – 2289)** 1184 (1000 – 1791)** 0.374## 
Platelet count (x109/mm3) 17 (13 – 48)** 24 (11 – 55)** 0.898## 
Haemoglobin (g/dl) 6.35 (5.0 – 7.1)** 6.7 (5.0 – 8.6)** 0.416## 
RPI 1.9 (0.9 – 3.1)** 3.7 (2.3 – 5.4)** 0.049## 
D-dimer (mg/l) 3.53 (2.4 – 5.4)** 1.1 (0.58 – 1.4)** 0.018## 
Urea (mmol/l) 10.3 (5.7 – 14.6)** 7.9 (4.9 – 11.5)** 0.234## 
Creatinine ( mol/l) 127 (97 – 252)** 92 (79 – 111)** 0.019## 
* N (% of total), **median (IQR), #Fisher Exact test, ##Mann Whitney U test 
The most commonly recorded form of neurological deficit in subjects presenting with HIV-associated 
TMA was confusion of varying severity (n = 15 cases, 60% of all recorded neurological deficit in the HIV 
positive subgroup, and occurring in 39.47% of all TMA presentations in HIV positive subjects). In one of 
these recorded cases of confusion subsequent investigation revealed associated cryptococcal 
meningitis. Generalized tonic-clonic seizures were recorded in three presentations of this subgroup (12% 
of neurological abnormality in this subgroup, occurring in 7.90% of all TMA presentations in HIV positive 
subjects). Two subjects developed focal neurological deficit, in both cases this took the form of 
hemiplegia (8% of all neurological deficit recorded in this subgroup during the course of this series, and 
5.26% of all presentations of HIV-associated TMA). Both of these subjects underwent CT scanning of the 
brain which revealed no obvious abnormality, subsequent lumbar puncture was also normal, and in 
both cases neurological deficit resolved with successful treatment of TMA. In five presentations 
neurological deficit was evidenced by headache and dizziness (representing 20% of all documented 
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neurological abnormality in the HIV positive subgroup, and 13.16% of all presentations of HIV-associated 
TMA). In contrast, in HIV negative subjects, neurological abnormality was mild involving only headache 
and / or dizziness; confusion, seizure and focal deficit were not observed. 
HIV-associated TMA in this series was not shown statistically to be associated with more severe 
microangiopathic haemolysis or consumptive coagulopathy as evidenced by haemoglobin 
concentration, LDH and platelet count (two-tailed Mann Whitney U test p = 0.416, p = 0.374, p = 0.989 
respectively) (table 3.2.2). Interestingly, RPI was significantly lower in subjects with HIV-associated TMA 
(p = 0.049) (table 3.2.2, figure 3.2.1).  
Figure 3.2 1 Box and whisker plot, comparison of RPI by HIV infection status 
Boxplot by  Group
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Renal dysfunction as evidenced by serum creatinine was significantly more severe in HIV-associated 
TMA (two-tailed Mann Whitney U test p = 0.019), and in 28 presentations (73.4%) presenting serum 
creatinine concentration exceeded the laboratory normal of 100 mol/l (table 3.2.2, figure 3.2.2).  
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Figure 3.2 2 Box and whisker plot, comparison of presenting creatinine concentration by HIV infection 
status 
Boxplot by  Group
Variable: Creatinine concentration at presentation (micmol/l)
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Consistent with previous reports, D-dimer concentration was higher in HIV-associated TMA (p = 0.018) 
(2) (table 3.2.2, figure 3.2.3). 
Figure 3.2 3 Box and whisker plot, comparison of presenting D-dimer concentration by HIV infection 
status 
Boxplot by  Group
Variable: D-dimer concentration at presentation (mg/l)
 Median 
 25%-75% 
 Min-Max 
Positiv e Negativ e
HIV inf ection status
-2
0
2
4
6
8
10
12
14
16
18
20
22
D
-d
im
e
r 
co
n
ce
n
tr
a
tio
n
 a
t p
re
se
n
ta
tio
n
 (
m
g
/l)
 
.26 
 
The median CD4 count in subjects presenting with HIV-associated TMA was 115 x 106/mm3 (IQR 42 – 
250 x 106/mm3 and range 6 – 744 x106/mm3). 91.89% of all subjects presenting with HIV-associated TMA 
met the WHO definition of advanced HIV infection (CD4 count below 350 x 106 / mm3) (109), and 64.86% 
of these subjects met the Centers for Disease Control definition of AIDS (CD4 count below 200 x 106 / 
mm3) (111). Analysis of a potential association between severity of TMA at presentation (as indicated by 
haemoglobin concentration, LDH activity, platelet count, D-dimer level, and urea and creatinine 
concentration) and severity of HIV infection (as determined by CD4 count) was made using the 
Spearman Rank Order Correlation test. No significant association was shown for any of these analysed 
parameters (for haemoglobin, p = 0.481, for LDH, p = 0.241, for platelet count, p = 0.093, for D-dimer, p 
= 0.849, for urea, p = 0.247, for creatinine, p = 0.178) (table 3.2.3).  
Table 3.2 3 Correlation of CD4 count with presenting parameters, HIV positive subjects 
 N R p 
LDH activity (IU/l) 37 0.197 0.241 
Platelet count (x109/mm3) 37 -0.280 0.093 
Haemoglobin (g/dl) 37 -0.119 0.481 
RPI 28 0.228 0.242 
D-dimer (mg/l) 22 0.043 0.849 
Urea (mmol/l) 37 -0.195 0.247 
Creatinine ( mol/l) 37 -0.226 0.178 
Spearman Rank Order method 
Further analysis of the possibility of an effect for severity of HIV infection as indicated by CD4 count in 
determining the severity of TMA presentation was undertaken by comparing presenting  parameters 
between subjects grouped by CD4 count into those with and without advanced HIV infection (World 
Health Organization definition, CD4 count < 350 x 106 / mm3) (106) and those with and without a CD4 
count indicative of AIDS (Centers for Disease Control definition, CD4 count < 200 x 106 / mm3) (111). In 
the former analysis the small number of patients with a CD4 count > 350 x 106 / mm3 (n = 3) precluded 
meaningful statistical analysis; nevertheless, analysed parameters showed striking similarity between 
the two groups (table 3.2.4). In the latter analysis, two-tailed Mann Whitney U testing failed to show 
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statistically significant differences in oral temperature, haemoglobin concentration, LDH activity, RPI, 
platelet count, D-dimer level, urea concentration or creatinine concentration (p = 0.290, p = 0.962, p = 
0.291, p = 0.781, p = 0.519, p = 0.821, p = 0.766, and p = 0.545 respectively) (table 3.2.4). 
Table 3.2 4 Comparison of presenting parameters in HIV positive subjects according to CDC and WHO 
definitions of advanced infection 
 CDC criteria WHO criteria 
 CD4 < 200* CD4 > 200* p CD4 < 350* CD4 > 350* 
LDH activity (IU/l) 
1489 
(1063–2287) 
1900 
(1337–2451) 
0.29 
1574 
(1101–2289) 
2509 
(1524–3493) 
Platelet count (x109/mm3) 
19 
(12 – 62) 
17 
(13 – 26) 
0.51 
18 
(13 – 54) 
12 
(7 – 17) 
Haemoglobin (g/dl) 
6.4 
(4.6 – 7.4) 
6.5 
(5.2 – 7.0) 
0.96 
6.4 
(5.0 – 7.2) 
5.35 
(3.8 – 6.9) 
RPI 
1.8 
(1.1 – 3.1) 
2.1 
(0.6 – 3.6) 
0.78 
1.95 
(0.9 – 3.1) 
2.4 
(0.6 – 4.2) 
D-dimer (mg/l) 
2.8 
(1.65 – 11.95) 
4.15 
(2.4 – 5.4) 
0.82 
3.53 
(2.4 – 5.4) 
1.3 
(n = 1) 
Urea (mmol/l) 
10.1 
(5.4 – 14.5) 
10.1 
(6.9 – 14.4) 
0.77 
10.1 
(5.7 – 14.6) 
8.1 
(2.8 – 13.4) 
Creatinine ( mol/l) 
132 
(101 – 265) 
125 
(91 – 198) 
0.54 
128 
(97 – 252) 
88 
(59 – 116) 
*CD4 x 106/mm3. Data is expressed as median (IQR) 
3.2.1 D-dimer level and HIV-associated TMA 
It has previously been suggested that higher D-dimer levels observed in cases of HIV-associated TMA 
may be indicative of an underlying unique pathophysiology of this disorder (2). Since D-dimer levels are 
representative of microthrombus formation (68) and since HIV-associated TMA may be more severe in 
presentation (51), the association of D-dimer levels with presenting parameters and with target organ 
injury in this series was tested; however, no statistically significant association was shown for D-dimer 
levels at presentation and presenting haemoglobin concentration (p = 0.203), LDH activity (p = 0.084), 
platelet count (p = 0.715), urea concentration (p = 0.242) or creatinine (p = 0.364) in subjects diagnosed 
with HIV-associated TMA (Spearman Rank Order Correlation test). 
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No statistically significant difference was found in D-dimer levels between subjects with neurological 
deficit (median D-dimer 2.85mg/l, IQR 2.4– 6.8mg/l) and those with no neurological deficit (median D-
dimer 5.4mg/l, IQR 3.9 – 5.4mg/l) using the Mann Whitney U test (p = 0.526). 
Although D-dimer levels were not shown to be correlated with presenting serum creatinine, additional 
analysis of the possible association between this potential marker of microthrombus formation and 
target organ injury was performed by testing for statistically significant difference in D-dimer levels 
between those subjects with HIV-associated TMA and renal dysfunction as evidenced by serum 
creatinine above the laboratory normal of 100 mol/l and those without evidence of renal dysfunction 
as evidenced by serum creatinine below laboratory normal of 100 mol/l. Although D-dimer levels were 
higher in those subjects with serum creatinine above 100 mol/l (median 3.9mg/l vs. 1.1mg/l), this 
difference was not statistically significant (p = 0.132). 
3.2.2 The role of infection in the severity of presentation of HIV-associated TMA 
HIV infection increases the risk of opportunistic infection (112), and such infection may exert a 
significant effect on several parameters associated with presentation with TMA. The reported 
prevalence of anaemia amongst hospitalized subjects ranges between 55% in those with mild infection 
to 70 – 90% in those with severe sepsis (113, 114) resulting from a complex underlying pathophysiology 
involving a combination of  haemodilution, blood sampling, impaired erythropoiesis, altered iron 
metabolism, and (critically for this study) haemolysis (114, 115). LDH is often significantly elevated in the 
serum of HIV positive subjects with Pneumocystis jiroveci pneumonia (116) but levels may also rise in 
other lower respiratory tract infections (117), and murine models indicate that systemic infection with 
bacteria including Salmonella species produces dramatic increases in serum LDH (118). 
Thrombocytopaenia is a not uncommon finding in infection occurring in 20 – 40% of septic subjects 
.29 
 
(114, 119). D-dimer levels may also be increased by infection (120), and sepsis is a common cause of 
acute kidney injury in HIV positive subjects, accounting for up to 84% of all such cases (121).  
In order to investigate whether concomitant infection may have contributed to the apparent severity of 
presentation of HIV-associated TMA, comparison was made of the presenting features of TMA in those 
subjects with evidence of infection versus those without such evidence (table 3.2.2.1). 
Table 3.2.2 1 Comparison of presenting parameters, HIV positive subjects with and without concomitant 
infection 
 
Subjects with 
concomitant infection 
Subjects without 
concomitant infection 
p* 
Oral temperature (oC) 37.0 (36 – 37.8) 37.0 (37 – 37.5) 0.721 
LDH activity (IU/l) 1763 (1335 – 2451) 1498 (1208 – 2285) 0.305 
Platelet count (x109/mm3) 17 (14 – 48) 15 (13 – 32) 0.657 
Haemoglobin (g/dl) 6.4 (5.2 – 7.4) 5.8 (4.5 – 7.0) 0.526 
RPI 1.1 (0.6 – 3.6) 2.1 (1.7 – 3.0) 0.347 
D-dimer (mg/l) 3.92 (2.5 – 5.4) 2.4 (0.9 – 4.0) 0.284 
Urea (mmol/l) 10.8 (7.2 – 15) 9.7 (5.0 – 13.9) 0.465 
Creatinine ( mol/l) 125 (101 – 239) 121 (89 – 375) 0.950 
CD4 count (x106/mm3) 229 (31 – 285) 82 (55 – 170) 0.359 
*Mann Whitney U test. Data is expressed as median (IQR). 
22 presentations of HIV-associated TMA were associated with evidence of concomitant infection 
(57.89% of all presentations of HIV-associated TMA).  
The following lists the concomitant infectious diseases diagnosed in subjects presenting with TMA 
during the course of this series (in descending order of frequency): 
1. Disseminated / extrapulmonary tuberculosis (n = 7, 30.43% of all concurrent infectious diseases) 
2. Gastroenteritis (n = 6, 26.08%)  
3. Pulmonary tuberculosis (n = 2, 8.70%) 
4. Urinary tract infection (n = 2, 8.70%) 
5. Pneumocystis jiroveci pneumonia (n = 2, 8.70%) 
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6. Community acquired pneumonia (n = 2, 8.70%) 
7. Bacterial meningitis (n = 1, 4.35%) 
8. Cryptococcus neoformans meningitis (n = 1, 4.35%) 
Presenting serum LDH activity and D-dimer level were higher in HIV positive subjects with evidence of 
infection, although these differences did not reach statistical significance (p = 0.305 and p = 0.284 
respectively). Statistically significant difference was similarly not shown for presenting oral temperature 
(in frequency or severity) haemoglobin concentration, platelet count, urea concentration, creatinine 
concentration, and frequency of neurological deficit between these two groups. Surprisingly, CD4 count 
was higher in those subjects with evidence of infection, although this difference too did not reach 
statistical significance. 
In view of the prevalence of gastroenteritis as a superadded infection in this series and the potential for 
dehydration due to gastro-intestinal fluid loss to contribute to renal dysfunction, further subanalysis was 
performed to evaluate severity of renal dysfunction as evidenced by creatinine in HIV positive subjects 
admitted with concomitant diarrhoea compared to HIV positive subjects without concomitant 
diarrhoea. The median presenting creatinine in subjects with diarrhoea was 297 mol/l (range 91 – 601 
and IQR 136 - 452 mol/l) compared to a median creatinine in subjects without diarrhoea of 119 mol/l 
(range 50 – 651, IQR 89 - 198 mol/l). Although suggestive that concomitant diarrhoea may have played 
a role in determining the severity of renal dysfunction in the presentation of HIV-associated TMA it 
should be noted that this difference did not reach statistical significance (p = 0.057) (figure 3.2.2.1).  
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Figure 3.2.2 1 Box and whisker plot, comparison of presenting creatinine concentration in HIV positive 
subjects with and without concomitant diarrhoea 
Boxplot by  Group
Variable: Creatinine concentration at presentation (micmol/l)
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When subjects who presented with concomitant diarrhoea were excluded from analysis presenting 
serum creatinine remained significantly higher in those with HIV-associated TMA compared to those HIV 
negative subjects presenting with the disorder (for HIV positive subjects without diarrhoea median 
creatinine was 125 mol/l with IQR 89 - 198 mol/l and range 50 – 651 mol/l, for HIV negative subjects 
without diarrhoea median creatinine was 91.5 mol/l with IQR 78.5 – 110.5 mol/l and range 63 – 
130 mol/l; p = 0.028). This suggests that whilst infectious diarrhoea may have played a role in affecting 
the severity of renal dysfunction in some cases of HIV-associated TMA, the disorder itself plays an 
important role in the apparently more severe renal dysfunction seen in HIV positive subjects. 
In conclusion, although opportunistic infection was a frequent concomitant diagnosis in subjects with 
HIV-associated TMA, the presence of infection does not appear to have significantly contributed to the 
abnormality of any of the parameters used in assessing the severity of the disorder. 
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3.3 Response to treatment of HIV-associated TMA 
The standard therapeutic protocol for HIV-associated TMA used at the Helen Joseph Hospital consists of 
plasma exchange using FFP as replacement fluid; plasma infusion as sole therapy is not used. 
Cryosupernatant plasma is substituted for FFP as plasma exchange replacement fluid in patients 
demonstrating a poor response to this initial treatment. In addition to plasmapheresis, all patients are 
initiated onto cART. Oral prednisone (1mg/kg per day) was routinely prescribed for the treatment of 
HIV-associated TMA until 2008, following which prednisone was used only in refractory cases of the 
disorder. Additional therapies such as other immunosuppressive drugs or splenectomy were not utilized 
for patients with HIV-associated TMA during the course of this series. 
 Thirty-two separate courses of plasma exchange were performed on 29 subjects presenting with HIV-
associated TMA (including episodes of recurrent disease)  during the course of the study period; six 
subjects demised before therapy could be instituted. Thus, 84.21% of all cases of HIV-associated TMA 
received plasma exchange therapy. Three subjects demised despite receiving plasma exchange (10.34% 
of all HIV positive subjects receiving plasma exchange, and 9.38% of plasma exchange therapy courses). 
In two of these subjects cause of death was ascribed to sepsis; one subject demised as a consequence of 
suspected pulmonary thromboembolism. Excluding these mortalities there were thus a total of 26 
survivors of HIV-associated TMA undergoing 29 separate courses of plasma exchange available for 
analysis of therapeutic response (table 3.3.1). 
Induction of remission as indicated by normalization of both platelet count and LDH activity to 
laboratory reference range for 2 consecutive days (as defined by the British Committee for Standards in 
Haematology) (79, 80) was attained in survivors of HIV-associated TMA after a median of 11 exchanges 
(range, 7 – 24 and IQR 8 - 15). Platelet count responded with greater rapidity than LDH activity (median 
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number of exchanges to normalize platelet count = 6 vs. median number of exchanges to normalize LDH 
activity = 11).  
Haemoglobin concentration rose by a median of 3.7 g/dl to a median of 10.2g/dl in response to therapy 
involving plasma exchange; it is likely that this improvement was facilitated by transfusion in many 
cases. 
Renal dysfunction similarly demonstrated improvement in response to plasma exchange with creatinine 
decreasing by a median of 37.0 mol/l to a median of 79 mol/l. 
Table 3.3 1 Therapeutic response of TMA to plasmapheresis in HIV positive subjects 
 Valid N 
(% of total) 
Median IQR Range 
Number of plasma exchanges required to 
induce remission 
29 (100) 11 8 - 15 7 - 24 
Number of plasma exchanges required to 
normalize platelets 
29 (100) 6 5 - 10 0 – 24 
Number of plasma exchanges required to 
normalize LDH 
29 (100) 11 8 - 15 7 – 24 
Haemoglobin concentration following plasma 
exchange (g/dl) 
29 (100) 10.2 8.9 – 11.1 7.1 – 17.1 
Haemoglobin concentration change from 
presentation in response to plasma exchange 
29 (100) 3.7 2.5 – 6.1 1.4 – 10.1 
Creatinine concentration following plasma 
exchange ( mol/l) 
29 (100) 79 71 - 93 42 – 371 
Change in creatinine concentration from 
presentation in response to plasma exchange 
( mol/l) 
29 (100) 37 8 – 74 -180 -311* 
*5 subjects (17.2% of subjects receiving plasmapheresis) demonstrated a deterioration in creatinine 
following therapy, the median increase in creatinine in these patients from presentation was 15 mol/l 
with IQR 6 – 177 mol/l) 
 
The response of neurological dysfunction to plasma exchange is difficult to retrospectively analyze; 
nevertheless, it is significant that both cases of focal neurological deficit in this series appear to have 
disappeared in response to plasma exchange. 
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In order to further evaluate the responsiveness of HIV-associated TMA to plasma exchange, data from 
HIV positive survivors of TMA was compared to that from HIV negative subjects receiving plasma 
exchange at the Helen Joseph Hospital during the same time period (n = 7). HIV-associated TMA was 
found to respond more rapidly than TMA in HIV negative subjects (n = 7), requiring fewer plasma 
exchange sessions to induce remission (median number of plasma exchanges to induce remission in HIV-
associated TMA = 11 vs. median number of plasma exchanges to induce remission in HIV negative 
subjects with TMA = 20, p = 0.013) (figure 3.3.1). 
Figure 3.3 1 Box and whisker plot, comparison of number of plasmapheresis sessions required to induce 
remission by HIV infection status 
Boxplot by Group
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As further evidence of the responsive nature of HIV-associated TMA to plasma exchange, it is noted that 
no statistically significant difference remained in creatinine concentration following plasma exchange 
therapy (as compared to a significantly higher creatinine in subjects with HIV-associated TMA at 
presentation) (p = 0.873 (figure 3.3.2)), and that the improvement in creatinine from presentation 
baseline was significantly larger in subjects with HIV-associated TMA (p = 0.027) (figure 3.3.3). 
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Figure 3.3 2 Box and whisker plot, comparison of creatinine concentration following induction of 
remission by plasmapheresis between HIV infection status groups 
Boxplot by Group
Variable: Change in creatinine from presentation following plasma exchange (micmol/l)
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Figure 3.3 3 Box and whisker plot, comparison of change in creatinine concentration from baseline 
following induction of remission by plasmapheresis between HIV infection status subgroups 
Boxplot by Group
Variable: Creatinine concentration following plasma exchange (micmol/l)
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It is possible that response to plasma exchange may be affected by 3 main factors; viz.: severity of TMA 
at presentation (before initiation of plasma exchange), severity of HIV infection, and choice of plasma 
infusant used. To investigate these hypotheses, association was tested between presenting parameters 
and CD4 count and the number of plasma exchanges required to induce remission (analysis of the effect 
of plasma infusant is presented separately below).  
Whilst presenting parameters (haemoglobin concentration, LDH activity, platelet count, D-dimer 
concentration, creatinine concentration) did not show statistically significant correlation (p = 0.586, p = 
0.475, p = 0.574, p = 0.763, and p = 0.477 respectively), inverse correlation was found for severity of HIV 
infection as determined by CD4 count and the number of plasma exchanges required to induce 
remission (R = - 0.496, p = 0.006) (figure 3.3.4).  
Figure 3.3 4 Correlation plot, number of plasma exchange sessions required to induce remission and CD4 
count at presentation 
Scatterplot of  Number of  plasma exchange sessions required to induce remission against CD4 count 
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In further univariate regression analysis using the least squares method, CD4 count at presentation was 
also shown to be a weak predictor of the number of plasma exchanges required to induce remission (R = 
0.396, R2 = 0.157, F = 5.01, p = 0.034). 
3.3.1 Effect of plasma infusant choice on therapeutic response 
In view of controversy regarding the potential for choice of plasma infusant to affect therapeutic 
response (84, 85), subanalysis was performed of the response of HIV-associated TMA to plasma 
exchange using FFP compared to cryosupernatant as plasma infusant. In 6 of the 29 separate courses of 
successful plasma exchange therapy described above, initial FFP was substituted by cryosupernatant 
plasma. These therapeutic courses were excluded from the following analysis, giving a total of 23 
courses of plasma exchange were performed using only FFP (n = 17) or only cryosupernatant plasma (n = 
6).  
In HIV-associated TMA, the use of cryosupernatant plasma did not result in a significant difference in the 
number of exchanges required to induce remission (median number of plasma exchanges in subjects 
receiving FFP = 10 with IQR 10 – 12, median number of plasma exchanges in subjects receiving 
cryosupernatant plasma = 10 with IQR 10 – 11; p = 0.944). Although haemoglobin concentration 
following plasma exchange was slightly higher in subjects receiving cryosupernatant plasma (median 
haemoglobin 11.2g/dl vs. 10.4 g/dl) and creatinine following plasma exchange slightly lower (median 
creatinine 62mmol/l vs. 79mmol/l), these differences were not statistically significant (p = 0.806 and p = 
0.175 respectively).  
3.3.2 Complications of plasma exchange 
Of 32 separate courses of plasma exchange prescribed for HIV-associated TMA during the course of this 
study, 29 were associated with a complication thereof (90.63%). Many subjects experienced multiple 
adverse events during the same course of plasma exchange. 
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Complications of plasma exchange retrospectively identified in these series categorized as either major 
(imminently life-threatening) or minor (not imminently life-threatening) are listed below and presented 
graphically in figure 3.3.2.1. 
1. Major complications: 
a. Line sepsis (occurring in 6 courses, 18.8% of plasmapheresis courses) 
b. Deep vein thrombosis (1 course, 3.1%) 
c. Pulmonary thromboembolism (1 course, 3.1%) 
2. Minor complications: 
a. Hypokalaemia (29 courses, 90.6%) 
b. Hypotension (12 courses, 37.5%) 
c. Hypocalcaemia (9 courses, 28.1%) 
d. Quintin line bleeding (7 courses, 21.9%) 
e. Allergic reaction (7 courses, 21.9%) 
f. Quintin line blockage necessitating line change (3 courses, 9.4%) 
g. Citrate reaction (3 courses, 9.4%) 
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Figure 3.3 5 Bar chart, complications of plasmapheresis in HIV-associated TMA 
 
Line sepsis was defined for the purposes of this analysis as laboratory documented microbiological 
colonization of a Quintin line.  Of a total of 6 episodes of proven line sepsis, in 3 cases a Staphylococcus 
aureus was cultured, whilst in one case each an Enterococcus faecalis, Coagulase negative 
Staphylococcus, and micrococcus species were cultured. All such episodes responded to Quintin line 
removal or replacement and appropriate antibiotic use. 
One subject was found to have demised during a session of plasma exchange. Retrospective review of 
this event appears consistent with sudden cardiac death. No other biochemical abnormality was found 
which may have contributed to this subject death, and at contemporaneous Mortality and Morbidity 
meeting the likely cause of death was considered to have been pulmonary embolism. 
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reading observed was 3.0 mmol/l (range 2.2 – 3.3 mmol/l). The median hypocalcaemic reading observed 
was 1.98 mmol/l (range 1.58 – 2.04 mmol/l).  
For the purposes of this analysis, hypotension was defined retrospectively as a blood pressure less than 
90mmHg (systolic) and 60mmHg (diastolic) occurring during the course of a session of plasma exchange. 
The median hypotensive blood pressure recorded under this definition was 77/53mmHg. All such 
episodes responded to colloid volume challenge, and in none of these episodes was inotropic support 
required. No evidence could be found to suggest that any of these episodes contributed to patient 
death.  
Bleeding occurred in 7 placements of Quintin lines for plasma exchange. In all cases these occurred 
immediately following line placement. In 3 of these episodes bleeding was limited to haematoma 
formation, and in the remaining four episodes this bleeding took the form of oozing from the entry site. 
No evidence could be found that these episodes contributed to hypotension, nor was evidence found to 
indicate that packed red cell transfusion was required as a direct result. 
Quintin line blockage was retrospectively defined as episodes in which the notes of the plasma exchange 
nurse suggested this to be his / her explanation for plasma exchange machine dysfunction, and which 
led to line replacement. Three such episodes were encountered during the course of this series. A deep 
vein thrombosis (the diagnosis being retrospectively validated through review of contemporaneous 
femoral vessel Doppler) occurred in one patient as a result of Quintin line insertion. 
Reactions to citrate, plasma infusant, and whole blood infusion were retrospectively analysed using 
contemporaneous plasma exchange nurse diagnoses. Plasma infusant reaction was most commonly 
diagnosed when subjects complained of a pruritic sensation during a session of plasma exchange, and 
was retrospectively deemed to have been of clinical significance when the nurse was shown to have 
considered the administration of an antihistamine or steroid to be necessary. The diagnosis of citrate 
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reaction was made when subjects reported the presence of paraesthesias most commonly described as 
“cramping” and usually affecting the digits during a session of plasma exchange. None of these episodes 
was shown to have been associated with patient death, and no record was found of any of these 
reactions having been serious enough to require intubation, inotrope use or ICU admission. No record 
was found to suggest a transfusion reaction during the course of this series. 
3.4 The prognosis of HIV-associated TMA 
3.4.1 Mortality 
Nine subject deaths were recorded during the period of this study; the mortality rate for HIV-associated 
TMA in this series was therefore 25.71%. This mortality subgroup comprised six female subjects and 
three male subjects, giving a female to male ratio of 2:1. All subjects were of Black African descent.  
The median time to death was 1 day (range, 1 – 60 days); five subjects (55.56%) demised within 24 
hours of presentation with HIV-associated TMA. Three subjects (33.33%) demised despite receiving 
plasma exchange, the remaining six subjects demised before plasma exchange could be instituted. Post 
mortem examination was not performed on any subject who demised during the course of this series, 
and cause of death is therefore here reported as recorded by the attending medical unit.  
Sepsis was the leading ascribed cause of subject death occurring in 4 subjects (44.44%), followed by 
TMA occurring in 3 subjects (33.33%), whilst 1 subject (1.11%) each demised as a result of 
hyperkalaemia (caused by microangiopathic haemolysis on a background of renal dysfunction) and 
cardiac arrest precipitated by suspected pulmonary embolism. Amongst subjects who demised despite 
receiving plasma exchange, two cases were ascribed to sepsis and one as a consequence of suspected 
pulmonary thromboembolism complicating Quintin line use. In both cases of death due to sepsis the 
subject was admitted with signs of infection; it is therefore unclear whether these deaths were a result 
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of this pre-existing infection or due to acquired Quintin line sepsis or immunosuppression arising as a 
result of plasmapheresis. 
Analysis of presenting features of HIV-associated TMA by mortality outcome is presented in table 3.4.1.  
Table 3.4 1 Comparison of presenting features of HIV-associated TMA by mortality outcome 
 Survivor subgroup Mortality subgroup  
 Median IQR Median IQR p 
Age (years) 32.5 27 - 38 41 31 – 49 0.077* 
Oral temperature (oC) 37.0 36.7 – 37.8 37.5 37.0 – 37.5 0.598* 
LDH activity (IU/l) 1563 1222 – 2245 1574 1475 – 3493 0.230* 
Platelet count (x109/mm3) 15 13 – 27 48 17 – 75 0.070* 
Haemoglobin (g/dl) 6.5 5.2 – 7.1 5.6 4.5 – 6.3 0.410* 
RPI 2.1 1.1 – 3.1 1.2 0.6 – 2.5 0.435* 
D-dimer (mg/l) 3.30 2.4 – 5.4 3.53 3.1 – 3.9 0.970* 
Urea (mmol/l) 9.4 4.8 – 13.4 22.5 14.4 – 31.2 0.0049* 
Creatinine ( mol/l) 117 89 – 175 298 239 – 518 0.0005* 
CD4 count (x106/mm3) 145 64 - 263 42.5 9.5 - 278 0.231* 
 N % of total N % of total p 
Sex 
F = 20 
M = 9 
F = 68.97 
M = 31.03 
F = 6 
M = 3 
F = 66.67 
M = 33.33 
1.000# 
Concomitant infection 14 51.85 7 77.78 0.252# 
Neurological deficit 19 73.08 6 66.67 0.694# 
Received plasma exchange 29 100 3 33.33 < 0.0001# 
*Mann Whitney U test, # Fisher Exact test 
The median age in subjects who demised was higher than that in survivors of HIV-associated TMA (41 vs. 
33 years), although this finding did not reach statistical significance (p = 0.077). Median CD4 count was 
lower in the mortality subgroup (42.5 x 106/mm3 vs. 133 x 106/mm3); this too did not reach statistical 
significance (p = 0.231). No difference was observed in sex ratios between these two groups (p = 1.00). 
No statistically significant difference was observed in presenting oral temperature (p = 0.598), 
haemoglobin concentration (p = 0.410), LDH activity (p = 0.230), platelet count (p = 0.070) or D-dimer 
level (p = 0.970). Although a clinical suspicion for concomitant opportunistic infection was more 
frequent in the mortality subgroup (66.67% vs. 51.85% of cases), this difference was not statistically 
significant (p = 0.252). 
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Target organ injury in the form of neurological deficit was less frequent in the mortality subgroup 
(66.67% vs. 73.08% of cases). Neurological deficit in subjects who demised most commonly took the 
form of confusion (55.56% of cases). Two episodes of seizure were recorded. The observed difference in 
the frequency of neurological deficit between subjects who demised and survivors of HIV-associated 
TMA was not found to be statistically significant (p = 0.694). In contrast, target organ injury in the form 
of renal dysfunction was significantly more severe in the mortality subgroup, as evidenced by a higher 
presenting median urea concentration (22.5mmol/l vs. 9.30mmol/l, p = 0.0049) and a higher presenting 
median creatinine concentration (298 mol/l vs. 117 mol/l, p = 0.0005). 
Plasma exchange was employed with greater frequency in survivors of HIV-associated TMA than in those 
HIV positive subjects diagnosed with the disorder who demised during the period of this review (100% 
of survivors received exchange compared to 33.33% of mortalities); this difference was statistically 
significant (p = 0.00003). 
3.4.1 Residual target organ dysfunction 
Analysis of the frequency and severity of residual neurological system disturbance in this series is limited 
by the retrospective nature thereof since objective data in this regard is in general poorly recorded; 
however, no indication was found in review of clinical case notes to indicate the persistence of 
neurological deficit in subjects included in this series. Analysis of objectively verifiable residual target 
organ dysfunction in HIV-associated TMA is therefore restricted to renal dysfunction. This is further 
considered appropriate given that renal injury appears significantly more severe in HIV-associated TMA 
than in TMA occurring in HIV negative subjects in this series, whereas the frequency of recorded 
neurological deficit was not different in these two forms of the disorder (thus suggesting that the kidney 
is an important site of injury in HIV-associated TMA). Analysis of residual renal dysfunction is, however, 
limited by the short duration of follow-up time from cessation of plasma exchange to the last recorded 
.44 
 
serum creatinine (median 3 days, range 0 – 32 days) and relatively low number of subjects (n = 18), as a 
result of the high rate of subjects defaulting outpatient follow-up immediately following discharge from 
hospital, and routine renal function measurement not being used as a standard screening test for TMA 
recurrence in the outpatient department, as well as the exclusion of data from subjects with recurrent 
episodes of HIV-associated TMA from this analysis. 
The median last recorded creatinine following cessation of plasmapheresis in in-patient HIV-positive 
survivors of TMA was 79 mol/l (IQR 66.5 – 113.5 mol/l and range 49 - 316 mol/l).  Last recorded 
serum creatinine of greater than the laboratory normal of 100 mol/l in in-patient survivors was noted in 
five cases (27.78% of the analysed subgroup); in this subgroup the median last recorded creatinine was 
169 mol/l (IQR 118 - 285 mol/l, range 109 - 316 mol/l). Deterioration in renal function as evidenced by 
a higher serum creatinine at last recorded outpatient follow-up compared to presenting serum 
creatinine was observed in two subjects (increase in creatinine 34 mol/l and 150 mol/l respectively). 
No subject in this series required the initiation of long term renal replacement therapy.  
Severity of HIV-associated TMA at presentation as evidenced by oral temperature, haemoglobin 
concentration, LDH activity and platelet count did not show correlation with last measured serum 
creatinine (p = 0.559, p = 0.342, p = 0.687, and p = 0.766 respectively). In contrast, presenting serum 
creatinine was found to have significant positive correlation with last recorded creatinine (R = 0.485, p = 
0.041) (figure 3.4.2.1), and D-dimer was found to have significant inverse correlation with this 
parameter (R = -0.740, p = 0.0025) (figure 3.4.2.2). No correlation was shown between either total 
number of plasma exchanges and number of plasma exchanges required to induce remission of TMA 
and severity of residual renal dysfunction as indicated by last recorded serum creatinine (p = 0.337 and p 
= 0.217 respectively). 
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Figure 3.4.2 1 Correlation plot, presenting creatinine concentration with last recorded creatinine 
concentration following induction of remission with plasmapheresis in HIV positive survivors of TMA 
Scatterplot of Last recorded creatinine concentration (micmol/l) against Creatinine concentration at
presentation (micmol/l)
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Figure 3.4.2 2 Correlation plot, presenting D-dimer concentration with last recorded creatinine 
concentration following induction of remission with plasmapheresis in HIV positive survivors of TMA 
Scatterplot of  last recorded creatinine concentration (micmol/l) against D-dimer concentration at
presentation (mg/l)
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3.4.2 TMA Recurrence 
International consensus classifies TMA recurrence as either exacerbation (recurrence occurring within 
30 days of induction of remission) or relapse (recurrence occurring more than 30 days after induction of 
remission) (1, 79, 80). During the period of study, there were 2 cases of exacerbation and 1 case of 
relapse of HIV-associated TMA documented in 3 subjects (11.54% of HIV positive subjects in this series). 
In contrast, there were 4 episodes of TMA recurrence in 3 HIV negative subjects (75% of all HIV negative 
subjects) during the same study period; this difference was statistically significant (p = 0.018 in two-
tailed Fisher Exact testing).  
Presentation with recurrent HIV-associated TMA was associated with a higher haemoglobin 
concentration (median 6.9g/dl with range3.9 – 8.6g/dl) compared to index presentation in the same 
subjects (median 6.1g/dl with range 4.1 – 9.3g/dl). LDH activity was also lower at recurrence (median 
1101IU/l, range 465 – 3410IU/l vs. median 2221IU/l, range 1208 – 2285IU/l at index presentation). 
Platelet count was higher at recurrence (median 18 x 109/mm3, range 10 – 127 x 109/mm3 vs. 11 x 
109/mm3, range 10 – 31 x 109/mm3), and creatinine was lower at recurrence (median 128 mol/l, range 
113 – 252 mol/l vs. median 191 mol/l, range 97 – 375 mol/l). In view of the small numbers of subjects 
(n = 3), meaningful statistical analysis of the significance of these observed differences was however not 
possible. 
All patients presenting with recurrent HIV-associated TMA were treated with plasmapheresis using 
cryosupernatant plasma as replacement fluid. Two patients (66.67% of patients with recurrence) 
received in addition oral prednisone.  
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4. Discussion 
4.1 The Epidemiology and Demographics of HIV-associated TMA 
Analysis of this series indicates that HIV infection was the most common aetiological factor involved in 
the development of TMA diagnosed at Helen Joseph Hospital between 2001 and 2009, with 89.74% of 
subjects presenting with the disorder being HIV positive. This finding is consistent with Gunther et al’s 
report that HIV was the dominant cause of TMA in the local context (54). In most cases, TMA was the 
presenting feature of HIV infection with 65.71% of subjects being diagnosed at presentation with HIV. 
Interrogation of data in this series indicates that HIV-associated TMA demonstrates a predilection to 
affect young Black women. It is likely however that the epidemiological patterns of HIV infection in 
South Africa have contributed substantially to this observed pattern. South Africans of Black African 
descent, and women in particular, are known to have the highest prevalence rates of HIV infection of all 
population groups (64, 122) and Black African women of reproductive age have been determined to 
have the highest seroprevalence rate of HIV infection of any race or age group in South Africa at 32.7% 
(123). Thus, demographic patterns of HIV-associated TMA in this single center series parallels those of 
HIV infection in South Africa.  
Such considerations are likely to account for the similarity this study shares with the only other reported 
series of HIV-associated TMA from South Africa (that of Novitzky et al) which also found a predominance 
of young Black African women affected with the disorder (51). In contrast, HIV-associated TMA as 
generally reported in the international literature appears to show a predilection for male patients (62). 
This apparent discrepancy is also explained by the demographics of HIV infection; in North America and 
Europe the infection is mainly acquired through male to male sex so that men carry the highest 
seroprevalence rates (with up to 73% of individuals living with HIV / AIDS in the United States being 
male) (63).  
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4.2 Presenting features of HIV-associated TMA 
Pyrexia appears to be a not infrequent presenting feature of HIV-associated TMA in this series, occurring 
in 41.2% of cases. The prevalence of pyrexia in HIV-associated TMA in the available literature is variable 
(Malak et al: 50% of cases, Rarick et al: 75% of cases) (103, 124); Novitzky et al reported a prevalence of 
pyrexia of 100%, although this reflects the use in this series of the Amorosi and Ultmann diagnostic 
criteria for TTP which require the presence of pyrexia (51). Analysis of the large Oklahoma TTP-HUS 
Registry found a prevalence of pyrexia in HIV-negative patients with TMA of 23%, considerably lower 
than that reported in case series of HIV-associated TMA (71, 51, 103, 124). This may indicate a tendency 
for pyrexia to be more frequent in HIV-associated TMA; however, analysis of this series does not show a 
significant difference in either the frequency of pyrexia or severity (as indicated by oral temperature) 
between HIV positive and negative patients with TMA.  
It should also be considered that pyrexia in HIV positive patients with TMA may arise from other 
concomitant disorders such as opportunistic infection; however, analysis did not indicate a significant 
difference in either the frequency or severity of pyrexia in those patients with evidence of infection 
compared to those with no evidence of infection. 
Neurological deficit has been reported in various case series to occur in between 61 – 69% of cases of 
HIV-associated TMA (51, 103, 124), the prevalence of neurological deficit in this series of 65.8% of cases 
is neatly consistent with these reports. Novitzky et al have reported that the most commonly 
encountered neurological abnormality in HIV-associated TMA is seizure (9 of 21 cases or 42.9%), 
followed by confusion (6 of 21 cases, 28.57%) (51); in contrast, in this series confusion was more 
common than seizure. It is likely that the retrospective nature of this series has led to an over-emphasis 
of confusion as a presenting feature of TMA since multiple confounding factors and the lack of an 
objective assessment of individual patient confusion (for example, using a mini-mental state 
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examination) may have resulted in observer bias. Focal neurological deficit is less common in this series 
than that reported by Novitzky et al (7.9% of cases vs. 17.4% of cases); it is possible that the presence of 
focal neurological deficit is under-reported in this series due to difficulties encountered by the 
examining doctor in accurately assessing focal deficit in the context of a confused and non-compliant 
subject; additionally, the ability to elicit subtle focal deficit is dependent on the clinical skill of the 
examining doctor and such factors are difficult to control for in retrospective review. 
The severity of presentation of HIV-associated TMA has been poorly studied in comparison to the 
disorder in HIV negative patients. Novitzky et al have reported that HIV-associated TMA is associated 
with more severe derangement of markers of microangiopathic haemolysis (lower haemoglobin 
concentration and higher LDH activity) and lower platelet count (51), findings that suggest that HIV-
associated TMA may be associated with a more severe microangiopathy. Analysis of the HJH data shows 
similar trends, although statistical significance was not reached in this series, possible due to the 
relatively small number of HIV negative subjects diagnosed with TMA during the period of study.  
The possibility that HIV-associated TMA results in more severe microangiopathy may explain the 
significantly disparate levels of D-dimer observed in this series consistent with Gunther and Dhlamini’s 
previous report (2). Since D-dimers reflect recent thrombus formation (68), high D-dimer levels may be 
indicative of the extent of recent microthrombus, and hence may be expected to show correlation with 
other parameters related to microthrombus load such as haemoglobin and LDH (microangiopathic 
haemolysis caused by circulating erythrocytes being forced through the lumina of vessels obstructed by 
thrombus) and platelet count (consumptive thrombocytopaenia resulting from the formation of platelet 
rich microthrombi). However, analysis of data from the HJH series did not show statistically significant 
correlation between these variables; nor were D-dimer levels shown to have meaningful statistical 
difference with regards to target organ dysfunction (specifically, neurological deficit and renal 
dysfunction).  
.50 
 
It is possible that the apparent severity of HIV-associated TMA over the disorder as encountered in HIV 
negative subjects may result from confounding factors related to the pathophysiology of HIV infection 
itself. For example, D-dimer levels are increased in HIV infection (68, 70) and are known to show 
significant positive correlation with the severity of HIV infection as indicated by HIV viral load (125); this 
association is thought to arise as a result of increased monocyte expression of tissue factor caused 
either directly by HIV RNA or indirectly as a result of opportunistic infection (69). Similarly, anaemia is 
not infrequently observed and becomes more common with advancing HIV infection (65). Analysis of 
the HJH data shows that RPI is significantly lower in subjects with HIV-associated TMA as compared to 
HIV negative patients presenting with the disorder; this suggests that suppression of erythropoiesis by a 
variety of factors related to HIV infection plays a role in the tendency for haemoglobin concentration to 
be lower at presentation in HIV-associated TMA.  
It is probable that such considerations underlie the observed significant disparity in severity of renal 
dysfunction in this series. Previous reports indicate that renal target organ injury is more severe in HIV-
associated TMA (51) consistent with the findings of this series; however, analysis suggests that in some 
cases concomitant diarrhoea is likely to have contributed to the severity of renal dysfunction observed 
(as indicated by more severe renal dysfunction in those subjects with diarrhoea compared to those 
without at a level approaching statistical significance), although the finding that renal dysfunction as 
indicated by presenting serum creatinine remained significantly more severe in subjects with HIV-
associated TMA when those with concomitant diarrhoea were excluded from comparison with HIV 
negative subjects with TMA suggests that the disorder itself is an important determinant of renal injury 
in HIV positive subjects. However, the influence other confounding factors such as the prevalence of 
underlying HIV-associated renal disease in an HIV positive cohort (67) cannot be excluded due to the 
retrospective nature of this study (in particular, the lack of urinalysis and renal biopsy makes assessment 
of this confounding factor impossible). 
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Analysis of the HJH series supports other case reports indicating that TMA is a feature of advanced HIV 
infection (51, 53, 54, 61) with a median CD4 count at presentation of 115 x106 / mm3. The WHO has 
defined a CD4 count below 350 x 106 /mm
3 as evidence of advanced HIV infection (109), whilst the 
Centers for Disease Control regards a CD4 count below 200 x 106 / mm3 as indicative of the acquired 
immunodeficiency syndrome (AIDS) (108); the median CD4 count of subjects in this series falls well 
within both of these definitions, and using WHO criteria 92.11% of subjects in this series can be 
considered to have advanced HIV infection. This observation accounts for the significant number of 
subjects in this series who presented with evidence of concomitant opportunistic infection (57.89% of 
presentations). Although concomitant opportunistic infection may have been expected to add to the 
severity of presentation of HIV-associated TMA (113 - 121), statistical analysis of this series does not 
support a significant role for opportunistic infection in determining presenting parameter aberration.  
CD4 count at presentation was not shown to correlate with presenting parameters; however, lack of 
significant linear association does not necessarily indicate that severity of TMA presentation is not 
affected by severity of HIV infection. CD4 count is susceptible to significant variation: normal diurnal 
variation can produce up to a 50% change in an individual patient (126), and physiological stressors 
(including exercise, diet, smoking, psychological stress, menstruation, and intercurrent infection) are 
known to alter CD4 count (127, 128). The retrospective nature of this study makes analysis of the effect 
of these confounding factors on individual subject CD4 count difficult, and they may account for the lack 
of correlation reported. An attempt was made to correct for potential individual subject CD4 count 
variation by analyzing the difference in severity of presenting parameter aberration according to 
severity of HIV infection determined by CD4 count as defined by the World Health Organization (109) 
and the Centers for Disease Control (111). Although no significant difference was found in either of 
these analyses, it should be considered that the majority of subjects in this series met CD4 count 
definitions of advanced HIV infection or AIDS as proposed by these bodies (109, 111); thus, 
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determination of statistical difference in accordance with these definitions is likely compromised by the 
relatively small numbers of subjects in this series who do not meet these definitions of severe HIV 
infection. 
4.3 Response to treatment of HIV-associated TMA 
Available literature detailing the response of HIV-associated TMA to plasma exchange is limited to 
isolated small case series reports in which therapeutic response is analysed only in terms of patient 
survival (38, 86 - 88). Patient survival in response to plasma exchange appears lower in HIV-associated 
TMA in some series in comparison to that generally reported for HIV negative patients (86 - 88); 
Novitzky et al have reported both better survival rates and a shorter duration of therapy using plasma 
infusion in a prospective cohort study comparing HIV positive and negative patients with TMA (51). 
Thus, although evidence suggests that plasma exchange may be a superior therapy to plasma infusion 
(77), this treatment remains poorly studied in HIV-associated TMA. 
Analysis of the HJH series indicates that HIV-associated TMA treated with plasmapheresis has a similar 
survival rate (90.6%) to that previously reported for HIV negative subjects (75 – 92%) (77). In comparison 
to a contemporaneous cohort of HIV negative subjects, HIV positive subjects in the HJH series required a 
significantly shorter duration of therapy to induce remission, consistent with Novitzky et al’s previously 
reported findings using plasma infusion as therapy (51). Additional evidence of the responsive nature of 
HIV-associated TMA to plasmapheresis may be found in the improvement in target organ injury 
(specifically, renal dysfunction) observed in this series. 
 Interestingly, induction of remission using plasmapheresis in the HJH series was more rapid than that 
reported by Novitzky et al using plasma infusion (median duration of plasma exchange: 11 days vs. 
median duration of plasma infusion: 21 days) (51), suggesting a possible superiority for plasma exchange 
over plasma infusion in HIV-associated TMA as previously reported for HIV negative patients (77). 
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However, the possible superiority of plasmapheresis over plasma infusion needs to be weighed against 
the cost and availability of the former therapy in a resource poor environment such as South Africa. 
Plasmapheresis requires expensive equipment operated by skilled technicians, and is not readily 
available outside of advanced care level institutions (51). As such, plasma infusion which has been 
shown by Novitzky et al to be effective in HIV-associated TMA may be an acceptable first line therapy for 
the disorder (51). The choice of plasma replacement used in plasma exchange does not appear to affect 
therapeutic response of HIV-associated TMA, consistent with the findings of a prospective study 
reported by Raife et al in HIV negative patients (85). 
CD4 count at presentation appears to correlate inversely with and predict (albeit weakly) the duration of 
plasma exchange required to induce remission of HIV-associated TMA. This suggests that the severity of 
HIV infection affects therapeutic responsiveness; however, this observation is at odds with other 
analyses of the HJH data which show no correlation between CD4 count and severity of disease 
presentation (assuming that the severity of disease presentation determines therapeutic response) or 
between presenting parameters and duration of therapy required to induce remission. A possible 
explanation for these discrepancies is that presenting parameters may have been affected by multiple 
factors in addition to HIV infection and TMA severity resulting in the loss of linear correlation. 
Plasma exchange is not without complications, and the risk of complication may be higher in HIV 
positive patients. 2.4% of (HIV negative) patients in the Oklahoma TTP-HUS Registry died as a result of 
complications directly attributable to plasma exchange and an additional 40% of patients in that series 
experienced non-fatal side effects related to this therapeutic modality (129). Although the incidence of 
fatal complications of plasma exchange in the HJH series compares favourably with this data (at 3.1% of 
cases), the incidence of non-fatal complications is dramatically higher than that reported by the 
Oklahoma TTP-HUS Registry (90.63% of cases vs. 25.72% of cases) (129) and more than double that 
reported by the Canadian Apheresis Study Group (which includes plasmapheresis performed for 
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indications other than TMA) in which 40% of patients experienced at least one complication related to 
the procedure (130). This disparity may however reflect the retrospective nature of this study. Whilst 
some adverse events such as hypokalaemia, hypocalcaemia, hypotension, line sepsis and deep vein 
thrombosis are readily verifiable in retrospective review, other events such as Quintin line blockage due 
to thrombosis, Quintin line bleeding; and allergic, citrate and transfusion reactions are less amenable to 
retrospective analysis. It is likely that the inability of this retrospective review to independently validate 
the accuracy of the diagnosis of adverse events in this series may have biased this analysis toward a 
view of plasma exchange therapy being associated with a higher frequency of adverse events than might 
be expected from the work of the Canadian Apheresis Study Group and the Oklahoma TTP-HUS Registry. 
4.4 The prognosis of HIV-associated TMA 
4.4.1  Mortality 
Analysis of this series suggests that HIV-associated TMA responds well to plasmapheresis and that 
survival rates in those subjects receiving this therapeutic modality are similar to those previously 
reported for HIV negative patients in local and international series (51, 77). However, since a significant 
number of HIV positive subjects demised before plasma exchange could be instituted, it could be argued 
that HIV-associated TMA is a more severe form of the disorder resulting in rapid deterioration and 
death, as reported in other series (86 - 88).  
Clarity in this regard was sought through interrogation of the ascribed causes of death in this series; 
sepsis arising from opportunistic infection was identified as the dominant cause (44.44% of mortalities), 
followed by TMA (33.33% of mortalities), suggesting that complications arising from HIV infection other 
than TMA may play an important role in determining patient outcome. Opportunistic infections are 
known to be an important predictor of outcome in HIV infected patients in general, having been 
reported as being the most frequent cause of death in seropositive individuals (131). Importantly, sepsis 
.55 
 
is known to act as a trigger and exacerbating factor for TMA in susceptible individuals (132). Thus HIV 
positive patients in an advanced stage of viral infection presenting with TMA which may itself carry a 
high mortality (86 – 88), face additive mortality risk arising directly from opportunistic infection (112, 
131) as well as from resultant opportunistic infection-related exacerbation of TMA (132). It is therefore 
likely that the discrepancy in the number of mortalities between the HIV positive and HIV negative 
patient groups of this series (although failing to reach statistical significance as a result of the paucity of 
HIV negative patients) and the rapidity of demise in a significant portion of this HIV positive mortality 
cohort (55.56% dying within 24 hours of presentation) reflects a “perfect storm” engendered by 
advanced HIV infection in which the resultant pathophysiological processes of opportunistic infection 
and TMA contribute together to mortality outcomes. 
In comparison to literature pertaining to mortality in TMA in HIV negative patients, analysis of the HJH 
series does not demonstrate significant differences between mortality and survivor subgroups of HIV-
associated TMA in terms of age (92), oral temperature (92), haemoglobin concentration (92, 93), or 
platelet count (93).  
Although neurological deficit has previously been shown to be more frequent in patients who do not 
survive TMA (91), in this series no significant such difference was shown between mortality and survivor 
subgroups, consistent with Wyllie et al’s observations (92). Wyllie et al’s methodology in reaching this 
conclusion has been subject to the criticism that this study included patients with mild presentations of 
neurological deficit in analysis resulting in biased outcome (90); similar considerations occasioned by the 
retrospective nature of this study (which prevents accurate determination of the severity of neurological 
abnormality such as confusion) may explain the apparent (albeit non-significant) higher frequency of 
neurological deficit in survivors of HIV-associated TMA. This finding is counter-intuitive as it is expected 
that target organ injury should be more frequent and more severe in those subjects who do not survive 
HIV-associated TMA. In comparison, renal dysfunction is readily analysed through review of documented 
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serum creatinine and urea.  In this series renal dysfunction was significantly more severe in those 
subjects with HIV-associated TMA who demised, consistent with data previously reported by Ferrari et al 
(93). Interpretation of the nature of renal dysfunction in this series appears to indicate a predominant 
role for acute kidney injury occurring as a direct consequence of TMA. Thus, severity of renal 
dysfunction may be considered a marker for endothelial injury. Since patients in this series did not 
develop uraemia severe enough to require initiation of dialysis it is likely that the association between 
mortality and severity of renal dysfunction reflects instead the significance of underlying endothelial 
injury. 
4.4.2 Residual target organ dysfunction 
Although limited by small subject numbers and lack of long term follow-up data, analysis of the HJH 
series demonstrates a good response of HIV-associated TMA to therapeutic intervention, with only 
25.78% of subjects having some degree of residual renal dysfunction (as evidenced by a serum 
creatinine in excess of the laboratory normal of 100 mol/l) following therapy compared to 83.33% of 
this cohort of subjects at presentation, and the general improvement in creatinine. Whilst other series 
have suggested that plasma exchange reduces the risk of end stage kidney disease by up to 81% (96) 
and results in the recovery of normal renal function in up to 73% (89) of cases of TMA in HIV negative 
patients, the possibility that other interventions (especially fluid resuscitation, given the possible role 
played by concomitant diarrhoea in determining the severity of renal dysfunction in this series) may 
have contributed substantially to plasmapheresis in the recovery of renal function in the HJH data 
cannot be fully excluded. Furthermore, reliance on creatinine only as a marker of residual renal deficit 
has important limitations. Schiepatti et al have shown that when the definition of renal deficit is 
extended to include the range of possible manifestations thereof (from hypertension to ongoing need 
for dialysis) up to 70% of patients with TMA may manifest some form of residual dysfunction (97). 
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The lack of presenting parameters in general to show correlation with renal function following therapy is 
consistent with the report of Hollenbeck (97). The inverse correlation between presenting D-dimer and 
last recorded creatinine is interesting and has not previously been investigated or reported. This 
suggests that the severity of microthrombus load at presentation may be associated with improvement 
in renal dysfunction with therapy. It has been proposed that the significantly elevated levels of D-dimer 
reported in HIV-associated TMA reflect the prothrombotic milieu of HIV infection with superimposition 
of TMA-related active microthrombus formation (2, 69, 70). D-dimer half-life is approximately 8 hours 
(133); the inverse association observed may therefore be explained by the hypothesis that the 
quantitative recovery of renal function is likely to be more significant in those subjects with more recent 
microthrombus formation, whilst those with longer standing microthrombus (with lower D-dimer levels) 
are likely to experience less recovery due to the development of irreversible renal injury.  
The positive correlation between presenting creatinine and creatinine at last follow-up following plasma 
exchange is consistent with Schiepatti et al’s observations (97). Schiepatti et al also reported the 
association of a poorer renal outcome with a lower haemoglobin concentration and higher platelet 
count at presentation; this disconnect in renal prognosis between haemoglobin concentration and 
platelet count was interpreted as evidence that the lower haemoglobin concentration at presentation in 
patients with poor renal outcomes was due to non-TMA causes, specifically (in the context of the 
association of poor renal outcomes with presenting creatinine) underlying but undiagnosed renal 
dysfunction (97). The lack of renal biopsies undertaken in the HJH series preclude definitive assessment 
of this possibility; nevertheless, the prevalence of renal disease in HIV positive subjects (67) makes this 
possibility worthy of consideration. In this regard the lack of association of residual renal dysfunction 
with haemoglobin concentration at presentation in the HJH series is not in keeping with Schiepatti et al’s 
report and may indicate that renal dysfunction in this series is mainly a result of acute kidney injury 
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caused by TMA. In this hypothesis, the severity of established acute renal injury at presentation is likely 
to determine the severity of persistent renal dysfunction following therapy. 
4.4.3 TMA Recurrence 
The frequency of TMA recurrence in this series was significantly lower in HIV positive subjects compared 
to HIV negative subjects. In general, TMA can be expected to recur in 15 – 30%  of cases (93, 100, 134), 
although the probability of recurrence of individual cases is strongly determined by underlying aetiology 
(27); HIV-associated TMA may recur less frequently but may be precipitated by cART non-compliance 
(38, 51). It is significant that most (67%) of recurrences of HIV-associated TMA occurred early as 
exacerbations, whilst only one patient experienced a relapse of TMA (i.e., recurrence more than 30 days 
after induction of remission). Since cART was initiated in all subjects with HIV-associated TMA in this 
series this suggests that this therapy is successful in preventing relapse, presumably through the 
mechanism of reducing HIV viral load. 
HIV-associated TMA appears to be less severe in presentation at recurrence compared to index 
presentation. It is likely that this reflects earlier diagnosis of the disorder due to improved subject and 
clinician surveillance; however, the potential effect of cART in ameliorating clinical severity cannot be 
fully excluded. 
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5 Conclusions 
HIV infection is the dominant aetiological factor in TMA in the community served by the Helen Joseph 
Hospital. HIV-associated TMA occurs in the context of advanced HIV infection. The disorder appears to 
show a predilection for young woman of Black African descent reflecting local demographic patterns of 
HIV infection. 
Renal target organ injury was more severe in HIV-associated TMA than that seen in HIV negative 
subjects with the disorder. It is possible that HIV-related diarrhoeal illnesses may have contributed to 
this finding. The observation that RPI was significantly lower in subjects with HIV-associated TMA 
similarly suggests that other disease processes related to HIV infection may play an important role in 
determining the severity of presentation of HIV-associated TMA. Opportunistic infection may be 
expected to contribute significantly to the severity of presentation (especially in a subject cohort in 
which advanced HIV infection is common such as the HJH series); however, this data does not support 
this hypothesis. 
 Analysis of this series confirms that HIV-associated TMA is associated with higher D-dimer levels than 
TMA occurring in HIV negative subjects, as previously reported (2). The significance of this association 
remains unclear, since D-dimer did not appear to correlate with other presenting parameters, was not 
higher in subjects with more severe target organ damage, did not correlate with therapeutic response, 
and was not higher in subjects who demised during the course of this study. D-dimer levels are known to 
be elevated in HIV infection and may merely represent a pre-existing prothrombotic state. An inverse 
association was observed between severity of residual renal deficit and D-dimer at presentation; this 
may indicate that D-dimer levels reflect recent microthrombus formation which is potentially reversible 
with therapy.  
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HIV-associated TMA responds well to plasma exchange, and induction of remission appears to require a 
shorter duration of therapy than is the case in HIV negative subjects. Target organ injury (neurological 
deficit and renal dysfunction) improves with plasmapheresis, although in the case of the latter adjuvant 
therapy with fluid replacement may have played an important role. The type of plasma infusant used 
(FFP or cryosupernatant plasma) does not appear to affect therapeutic response. Presenting parameters 
do not appear to affect the duration of plasmapheresis; however, subjects with more advanced HIV 
infection (as indicated by lower CD4 count) require a longer duration of therapy to achieve remission. 
Side effects of plasma exchange are not uncommon but are usually mild, and plasmapheresis is 
efficacious in reducing mortality. 
The mortality rate of HIV positive subjects with TMA in this series is similar to that reported for HIV 
negative patients in other series. Severe renal dysfunction at presentation may identify subjects likely to 
demise. Timeous intervention with plasma exchange is required to avert death. 
Residual target organ dysfunction following plasma exchange is rare in this series. Presenting D-dimer 
level appears to show inverse association with creatinine at follow-up through possible mechanisms 
outlined above. Presenting creatinine shows positive correlation with creatinine at follow-up, indicating 
that the severity of established renal acute injury (or chronic underlying disease) plays a role in 
determining the degree of recovery possible in cases of HIV-associated TMA. 
HIV-associated TMA rarely recurs, but may be precipitated by non-compliance with cART. In the event of 
recurrence, TMA appears to be milder as a result of earlier detection. 
In summary, HIV infection is a common cause of TMA in the local setting. HIV-associated TMA in this 
series is characterized by marked renal dysfunction. The disorder responds rapidly to plasma exchange 
and initiation of cART, interventions which effectively prevent death and improve target organ 
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dysfunction. Although HIV-associated TMA is rare, the efficacy of plasmapheresis mandates that 
clinicians should have a high index of suspicion for the disorder in HIV infected patients. 
6 Limitations 
The following limitations are identified in respect of this study: 
1. The retrospective nature of this study: TMA is comparatively rare, with an estimated annual 
incidence of 4 cases / 1 000 000 people (48), which necessitated the retrospective method 
employed. Although this approach has generated a large number of presentations for analysis 
compared to other reports available in the international literature, retrospective analysis carries 
with it inherent weaknesses which may result in incomplete or inaccurate results. Although 
these effects are mitigated in this study through reliance on objective laboratory data, it is 
possible that these weaknesses have compromised the analysis of clinical parameters.  
2. The small sample size analysed: although this series is comparatively large in comparison to 
other series of HIV-associated TMA reported in the literature, total sample size remains small. 
This resulted in non-normal distribution for most parameters analysed in this series as 
evidenced by the Shapiro-Wilk W test and in consideration of the Central Limit Theorem. This 
was compensated for in statistical analysis using non-parametric methods of significance testing; 
however, it should be considered that small sample size carries with it the inherent risks of bias. 
3. The disparity in sample size between HIV positive and HIV negative subject groups: The small 
total number of subjects in this series found particular expression in the HIV negative cohort. As 
a result, the HIV positive and negative cohort had a significant discrepancy in size. Non-
parametric testing using the Mann Whitney U test and the Fisher Exact test were employed in 
an attempt to compensate for these differences. Nevertheless it should be considered that the 
small number of HIV negative subjects exposes the analysis of this series to potential bias. 
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4. The short duration of follow-up: Analysis of long-term outcomes of patients included in this 
series has been hampered by a relatively short duration of individual subject follow-up. This lack 
of long-term follow-up has made a full and accurate analysis of TMA recurrence and residual 
renal dysfunction (which might account for considerable morbidity) difficult.  
5. The lack of histopathological material: The lack of renal biopsies in this series may have resulted 
in a failure to include cases of renal-limited HIV-associated TMA in this analysis. This may have 
resulted in a bias of the interpretation of the presentation of HIV-associated TMA toward a 
more severe systemic presentation of HIV-associated TMA form of the disorder. However, 
available data suggests that renal limited HIV-associated TMA is comparatively rare accounting 
for only 7 – 15% of presentations (58, 72) so that bias if so engendered is likely to be relatively 
mild. 
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7 Appendix 
 
Table 7 A. Laboratory normal values, Helen Joseph Hospital 
Parameter Laboratory normal range* 
LDH activity (IU/litre) 100 – 200 
Platelet count (x109/mm3) 137 – 373 
Haemoglobin concentration (g/dl) 14.3 – 18.3 
Reticulocyte production index (RPI) < 1: inadequate marrow response 
1 – 2: adequate marrow response 
D-dimer concentration (mg/l) 0.00 – 0.25 
Urea concentration (mmol/l) 2.1 – 7.1 
Creatinine concentration ( mol/l) 64 – 100 
Calcium concentration (mmol/l) 2.15 – 2.50 
Potassium concentration (mmol/l) 3.5 – 5.1 
CD4 count (x106/mm3) 500 – 2010 
*As defined by the National Health Laboratory Service on-site laboratory, Helen Joseph Hospital 
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